|
5th International AIDS Society Conference on HIV Pathogenesis and TreatmentCape Town, South Africa - July 19-22, 2009 |
Main TOC Monday TOC Tuesday TOC Wednesday TOC
Cite as: IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: Abstract No. xx
where xx is the abstract number.
| Monday – Oral Sessions MOAA1 – Control of HIV by Cellular Immunity |
|
| MOAA101 | THE HLA-C (GROUP 2) RESTRICTED NATURAL KILLER CELL STIMULATORY RECEPTOR, KIR2DS1, PREFERENTIALLY RECOGNIZES HIV-1 INFECTED CELLS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:13 (abstract no. MOPL101) W. Carr1,2, V. Naranbhai2, H. Arase3, M. Carrington4, T. Ndung'u2, L. Lanier5, M. Altfeld1 This finding provides the first evidence that HIV-1 infection can modulate innate immune responses in an HLA-restricted manner. Taking into consideration the recent evidence that NK cells may have immunological memory (Sun et al, Nature 2009) we offer a new paradigm for understanding innate immune protection from HIV-1 disease. We introduce a model that blurs the line between innate and adaptive immunity; and reflects the inherent advantages of NK cell diversity, which has important implications for vaccine design. |
| MOAA102 | CHARACTERIZATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE I IN THE ACUTE/EARLY PHASE OF INFECTION IN THE INDIVIDUALS WHO SUBSEQUENTLY BECOME VIREMIA CONTROLLERS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:13 (abstract no. MOAA102) T. Miura1,2,3, Z. Brumme2, C. Brumme2, B. Block2, M. Brockman2, A. Trocha2, F. Pereyra2, D. Kaufmann2, A. Iwamoto1, H. Jessen4, E. Rosenberg2, A. Kelleher5, M. Markowitz6, S. Little7, B. Walker2,3, AIEDRP Network Persons who control HIV viremia after acute infection have reduced viral fitness, linked to Gag-Protease, which is attributable to the complex factors including fitness cost by de novo CTL escape mutations in the recipients, transmission of multiple-class drug resistant strains and transmission of the attenuated escape variants from B57+donors. |
| MOAA103 | HLA-RESTRICTED EPITOPES FROM AUTOLOGOUS SEQUENCES AS A TOOL TO CHARACTERIZE THE ACTUAL BREADTH OF IMMUNE RESPONSES IN ELITE CONTROLLERS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:13 (abstract no. MOAA103) L.F. Tarosso1, M.M. Sauer2, H. Tomiyama2, S. Sanabani3, E.C. Sabino3, J. Sidney4, A. Sette4, D.I. Watkins5, E.G. Kallas1,2 These findings suggest that immune responses assessed using 15-mer overlap by 11 aminoacids may underrepresent the real breadth of immune control of the infecting virus and that the knowledge about succesful responses in ECs could be improved reviewing the methods employed. |
| MOAA104 | TCR CLONOTYPES RESPONDING TO AN IMMMUNODOMINANT HLA-B*27 RESTRICTED EPITOPE ARE RELATIVELY STABLE OVER EXTENDED PERIODS BUT THEIR DIVERSITY DOES NOT CORRELATE WITH VIRAL ESCAPE IN HIV-1 INFECTED LONG TERM NON-PROGRESSORS (LTNP) IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:13 (abstract no. MOAA104) D. van Bockel1, P. Ammaranond2, V. Venturi3, M. Davenport4, D. Price5, D. Douek6, J. Zaunders7, L. Gelgor1, J. Kaldor1, D. Cooper1, A. Kelleher1 Although escape from CTL responses in HLA-B27 positive patients appears to impact on disease progression, the determinates of escape are not related to known predictors of disease progression or the breadth of the TCR response. |
| MOAA105 | DISSECTING T CELL RESPONSIVENESS TO γC-CYTOKINE IN HIV INFECTED SUBJECTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:14 (abstract no. MOAA105) C. Riou1, N. Malatsi1, G. De Bruyn2, R.-P. Sekaly3, C.M. Gray1 Our results indicate that T cell differentiation affects γC-cytokine responsiveness where terminally differentiated cells lose their ability to respond to cytokines. In HIV-specific cells, impaired responsiveness to IL-2 could play a role in generating functionally inefficient antigen-specific cells. Thus, differentiation status and antigen specificity both appear to have a role in determining responsiveness to immune activation signals. |
| MOAA2 – Subversion of Immune Responses in HIV Infection |
|
| MOAA201 | HIV-1 Vpr-MEDIATED ATR ACTIVATION AND G2 CELL-CYCLE ARREST INDUCE UP-REGULATION OF NKG2D LIGANDS AND ACTIVATE NK CELL-MEDIATED KILLING IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:14 (abstract no. MOAA201) J. Richard, S. Sindhu, J.-P. Belzile, É.A. Cohen Our data reveal that Vpr-mediated ATR activation and G2 arrest modulate NK cell cytotoxic activity through an up-regulation of NKG2D ligands. This immuno-modulatory activity of HIV-1 Vpr may contribute to CD4+ T cell depletion as well as NK cell dysfunction due to sustained effector activation. |
| MOAA202 | DIFFERENTIAL PLASMA TRAIL AND IFN-α LEVELS FOLLOWING THERAPY INTERRUPTION IN CHRONIC HIV-1 INFECTION: INABILITY OF PDC TO DIRECTLY LYSIS HIV-INFECTED AUTOLOGOUS CD4+ T CELLS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:14 (abstract no. MOAA202) J. Chehimi1, E. Papasavvas1, C. Tomescu1, B. Gekonge1, K. Vinekar2, C. Carty3, A. Hancock1, M. Pistilli1, G. Reynolds1, K. Mounzer4, J. Kostman3, L.J. Montaner1 We observe a lack of association between IFN-α, enhanced TRAIL and DR5 expression in circulating CD4 T cells in vivo. Importantly, our combined results findings suggest a predominant antiviral role for PDC if remaining functional rather than having a predominant role during viremia augmenting DR5-dependent CD4 T cell apoptosis. |
| MOAA203 | IMPACT OF NK-DC CROSSTALK ON HIV REPLICATION AND PERSISTENCE IN DENDRITIC CELLS – CONTRIBUTION OF HMGB1 IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:14 (abstract no. MOAA203) M.-L. Gougeon, H. Saidi, M.-T. Melki This study provides evidence for the crucial role of NK-DC crosstalk in promoting viral replication and dissemination in DCs, and it challenges the question of the in vivo involvement of HMGB1 in HIV-1 replication and replenishment of viral reservoirs in DCs. |
| MOAA204 | ANTIGEN-PRESENTING CELLS REPRESENT POTENTIAL TARGETS FOR R5 TROPIC HIV-1 INFECTION IN THE FIRST TRIMESTER PREGNANCY HUMAN UTERINE MUCOSA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:15 (abstract no. MOAA204) R. Marlin1, M.-T. Nugeyre1, C. de Truchis2, N. Berkane3, A. Gervaise2, F. Barré-Sinoussi1, E. Menu1 The permissivity of decidual tissue to HIV-1 infection in vitro suggest that in vivo a first level of control of HIV-1 in utero mother-to-child transmission occurs, preceeding and in addition to the control previously demonstrated by the placenta. |
| MOAA205 | PD-1 INDUCED IL-10 PRODUCTION BY MONOCYTES IMPAIRS CD4 T-CELL ACTIVATION DURING HIV INFECTION IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:15 (abstract no. MOAA205) E.A. Said1, L. Trautmann1, F.P. Dupuy1, Y. Zhang1, Y. Shi1, D.C. Douek2, E. Haddad1, R.P. Sekaly1 We demonstrate a mechanism by which microbial products and inflammatory cytokines, present at high levels in the blood of HIV-infected donors, lead to the up-regulation of PD-1 on monocytes during HIV infection. Triggering through PD-1 by its physiological ligand PD-L1 induces IL-10 production, by monocytes, which inhibits T-cell responses. |
| MOAB1 – Paediatric ART: Successes and Challenges |
|
| MOAB101 | SURVIVAL RATES FOLLOWING EXPANSION OF THE NATIONAL PEDIATRIC ANTIRETROVIRAL TREATMENT PROGRAM, THAILAND, 2000-2005 IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:15 (abstract no. MOAB101) M. McConnell1, P. Yuktanont2, U. Siangphoe1, N. Pattarapayoon2, S. Kohreanudom2, R. Lolekha1, P.A. Mock1, S. Chasombat2, S. Thanprasertsuk3 National expansion of the pediatric ART program in Thailand demonstrates good survival rates, including at district/community hospitals. Poorer outcomes were associated with advanced disease at baseline; efforts to promote early initiation of ART for eligible children should be strengthened. |
| MOAB102 | HIGH SURVIVAL AND TREATMENT SUCCESS SUSTAINED AFTER UP TO THREE YEARS OF ART FOR CHILDREN IN CAMBODIA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:15 (abstract no. MOAB102) P. Isaakidis1, M.-E. Raguenaud1, V. Te2, C.S. Tray3, K. Akao3, V. Kumar3, S. Ngin4, E. Nerrienet4, R. Zachariah5 Good survival rate, immunological restoration and viral suppression can be achieved and sustained after three years of ART among children in resource-constrained settings. Increased access to routine virological measurements is needed in these settings to allow for timely and accurate diagnosis of treatment failure. |
| MOAB103 | RANDOMIZED CLINICAL TRIAL OF SWITCHING TO NEVIRAPINE-BASED THERAPY FOR INFECTED CHILDREN EXPOSED TO NEVIRAPINE PROPHYLAXIS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOAB103) A. Coovadia1, E. Abrams2 R. Strehlau1, L. Martens1, G. Sherman3, T. Meyers4, L. Kuhn5, NEVEREST Study Team Our study provides proof of concept that re-use of nevirapine following successful suppression on LPV/rbased therapy is possible under some circumstances for HIV-infected children exposed to nevirapine prophylaxis. Further research is necessary to determine the circumstances and interventions required to safely re-use this agent. |
| MOAB104 | VIROLOGIC FAILURE AND SECOND-LINE ANTIRETROVIRAL THERAPY (ART) IN CHILDREN IN SOUTH AFRICA: THE INTERNATIONAL EPIDEMIOLOGIC DATABASES TO EVALUATE AIDS (IeDEA) SOUTHERN AFRICA COLLABORATION IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOAB104) M.-A. Davies1, R. Wood2,3, G. Van Cutsem4,5, J. Giddy6, B. Eley7,8, H. Rabie9, H. Moultrie10,11, K. Technau10,12, A. Boulle1, International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Approximately 50% of children with virologic failure were not switched, with a notable delay between failure and switching. Ritonavir strongly independently predicts virologic failure. |
| MOAB105 | HOW WELL DO THE REVISED WORLD HEALTH ORGANISATION WEIGHT-BASED DOSING GUIDELINES FOR LOPINAVIR/RITONAVIR IN INFANTS AND CHILDREN CORRELATE WITH BODY SURFACE AREA-BASED DOSING RECOMMENDATIONS? IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOAB105) J. Nuttall1, B. Eley1, M.-A. Davies2 The revised WHO weight-based dosing guidelines for L/r solution provide doses in excess of 300/75 mg/m2, particularly for children <6 months of age. Pharmacokinetic studies using weight-based L/r dosing strategies in infants and incorporating careful monitoring of drug levels and toxicity should be undertaken. |
| MOAB2 – Cardiovascular Disease: to HAART or not to HAART |
|
| MOAB202 | ABACAVIR USE AND RISK OF ACUTE MYOCARDIAL INFARCTION AND CEREBROVASCULAR DISEASE IN THE HAART ERA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:16 (abstract no. MOAB202) R. Bedimo1,2, A. Westfall3, H. Drechsler1,2, P. Tebas4 In our cohort, cumulative exposure to ABC was associated with a modest, non-statistically significant increase in AMI and CVA risks. The association of ABC use with AMI was much weaker after adjusting for traditional cardiovascular risk factors. The AMI risk appears to be lowest for patients not receiving ART. |
| MOAB203 | NO EVIDENCE FOR RECENT ABACAVIR/LAMIVUDINE USE IN PROMOTING INFLAMMATION, ENDOTHELIAL DYSFUNCTION, HYPERCOAGULABILITY, OR INSULIN RESISTANCE IN VIROLOGICALLY SUPPRESSED HIV-INFECTED PATIENTS: A SUBSTUDY OF THE BICOMBO RANDOMIZED CLINICAL TRIAL (ISRCTN61891868) IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOAB203) E. Martinez1, M. Larrousse1, I. Perez1, M. Loncá1, D. Podzamczer2, F. Gutierrez3, R. Deulofeu1, R. Casamitjana1, J. C. Reverter1, J. Mallolas1, J. Pich1, J.M. Gatell1, for the BICOMBO Study Group These results do not support a role of recent ABC/3TC use in promoting inflammation, endothelial dysfunction, hypercoagulability, or insulin resistance in virologically suppressed HIV-infected patients. |
| MOAB204 | DURATION OF HIV INFECTION IS ASSOCIATED WITH CAROTID ARTERY STIFFNESS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOAB204) E.C. Seaberg1, A.R. Sharrett1, H.N. Hodis2, W.J. Mack2, L.A. Kingsley3, L. Benning1, R.C. Kaplan4, J.P. Phair5, Multicenter AIDS Cohort Study (MACS) Adjusted for CVD risk factors, prolonged HIV infection was independently associated with increased carotid artery stiffness, providing evidence that HIV may be associated with CVD via pathways that do not directly involve atherosclerosis/CVD disease risk factors. |
| MOAB205 | CORONARY VASOMOTOR FUNCTION IS REDUCED AFTER INITIATION OF ANTIRETROVIRAL THERAPY IN TREATMENT NAÏVE HIV PATIENTS: A PROSPECTIVE MYOCARDIAL PERFUSION PET STUDY IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOAB205) U.S. Kristoffersen1,2, A.-M. Lebech3, J. Gerstoft4, N. Wiinberg5, H. Gutte1,2, C.L. Petersen5, A. Kjaer1,2 Coronary vasomotor function was compromised by a decrease in maximal hyperaemic perfusion one month after initiation of ART in treatment naïve HIV patients. These findings indicate causality between ART initiation and impaired vasomotor function and thus support the findings of increased risk of CVD in recently presented observational studies. Additionally, no change was observed in CPR, suggesting other responsible mechanisms than those typical for endothelial dysfunction. |
| MOAB206 | A 14-DAY TREATMENT WITH A CYCLOOXYGENASE 2 (COX-2) INHIBITOR REDUCES INFLAMMATION IN THE LYMPHOID TISSUES OF HIV-INFECTED PATIENTS WITHOUT HAART - A PILOT STUDY WITH POSITRON EMISSION TOMOGRAPHY (PET/CT) ASSESSMENT IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOAB206) N. Witvrouw1, G. Darcis2, G. Gaudray3, N. Schaaf-Lafontaine4, R. Hustinx5, K. Schepers6, M. Moutschen2, C. Meuris2 PGE2 secretion plays a role in the increased metabolic activity of lymphoid tissues in HIV-infected patients without HAART and might also take part in their immunologic abnormalities. |
| MOAD1 – Innovative Methods for Effectively Delivering HIV Care Interventions |
|
| MOAD101 | THE IMPACT OF HOME-BASED COMPARED WITH FACILITY-BASED HIV-CARE ON VIROLOGIC FAILURE AND MORTALITY: A CLUSTER RANDOMISED TRIAL IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOAD101) S. Jaffar1, B. Amuron2, J. Levin2, J. Birungi3, G. Namara2, C. Nabiryo3, A. Coutinho4, H. Grosskurth2,5 Excellent outcomes were achieved in both facility and home-based HIV care. Complex treatments in Africa can be delivered effectively nearer to patients' homes without frequent support from clinical staff. |
| MOAD102 | NURSE-DRIVEN, COMMUNITY-SUPPORTED HIV/AIDS CARE AND TREATMENT: 2 YEAR ANTIRETROVIRAL
TREATMENT OUTCOMES FROM A PRIMARY CARE LEVEL PROGRAMME IN RURAL LESOTHO IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOAD102) R. Cohen1, S. Lynch1, H. Bygrave1, N. Vlahakis1, L. Makakole2, N. Ford3, E. Goemaere4 The two-year outcomes of this nurse-driven, community-supported programme provide further evidence that HIV/AIDS care and treatment can be provided effectively at health centres, to the benefit of primary health care services. The programme validates several critical areas for task-shifting that are being considered by other countries in the region, including nurse-initiated and managed ART for adults and children, and lay counsellor-supported testing, adherence, and case management. |
| MOAD103 | WOMEN ACCESSING INTEGRATED SERVICES: WHO ARE THEY AND WHAT DO THEY NEED? IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOAD103) S. Adamchak1, B. Janowitz1, R. Homan2, T. Grey1, E. Keyes1 Screening women for their call for complementary services to address unmet need for contraception or HIV testing is not routinely taking place, though services are nominally integrated. Providers must become more systematic in routinely assessing clients for the need for services, and deliver services or make appropriate referrals. |
| MOAD104 | EVALUATING THE BENEFITS OF INCORPORATING TRADITIONAL BIRTH ATTENDANTS IN PMTCT SERVICE DELIVERY IN LILONGWE SEMI-URBAN DISTRICT IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOAC104) C. Kabondo1, C. Zimba1, E. Kamanga1, G. Hamela1, I. Mofolo1, B. Bulla1, F. Martinson1,2, I. Hoffman2, C. van der Horst2, M. Hosseinipour1,2 TBAs can supplement efforts to provide PMTCT services in communities if properly trained and supervised. Provision of transport would allow HIV positive women to deliver in health facilities. There is need to devise a proper mechanism to track referrals from TBAs to health facilities. |
| MOAD105 | LONG TERM PROGRAMMATIC OUTCOMES FOR ADULTS AND CHILDREN AT A PRIMARY HEALTH CARE ANTIRETROVIRAL CLINIC IN SOUTH AFRICA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOAD105) R. Kaplan1, L.-G. Bekker1,2, E. Zwane3, E. Campbell1, C. Orrell1, R. Wood1,2 Favourable paediatric outcomes provide support for integrated adult and paediatric services in community ART clinics. |
| Poster Discussions MOPDA1 – HLA Pathogen Interactions |
|
| MOPDA101 | IDENTIFICATION OF ARCHIVAL VIRUS FROM LATER-STAGE SAMPLES USING ULTRA-DEEP SEQUENCING IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOPDA101) D.M. Dudley1, M.L. Budde2, S.L. O'Connor1, B.N. Bimber2, R.W. Wiseman3, D.H. O'Connor1,3 We have developed a method utilizing ultra-deep sequencing of subsets of PBMCs to identify early archival virus. We are currently using this method with clinical human samples to study early CTL escape in HIV. Identification of HIV escape mutants from a presumably strong early CTL response may inform which CTL responses to elicit in an effective HIV vaccine. This method will also hopefully provide viral sequence information when acute-stage samples are unavailable. |
| MOPDA102 | IMPACT OF HLA CLASS I-ASSOCIATED IMMUNE PRESSURE ON IN VITRO REPLICATION CAPACITY OF HIV VARIANTS ENCODING CLINICALLY-DERIVED GAG-PROTEASE IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOPDA102) M.A. Brockman1,2, Z.L. Brumme1,2,3, C.J. Brumme1, J. Sela1, P. Rosato1, T. Miura4, J.M. Carlson5, A. Schneidewind6, C. McCullough2, J. Spring2, R. McGovern2, D. Chan2, C. Woods2, W. Dong2, T. Mo2, D. Heckerman5, B.D. Walker1, P. R. Harrigan2, T.M. Allen1 This study is the most comprehensive analysis of HLA-associated immune pressure on HIV replication to date and suggests a relevant role for Gag-Protease sequence variation on pathogenesis. Results support a dominant influence of HLA-B on RC and highlight a complex relationship between immune escape and compensatory mutations. |
| MOPDA103 | THE IMPACTS OF HLA CLASS I ALLELES ON HIV-1 PLASMA VIRUS LOADS IN A UNIQUE ASIAN POPULATION WITH A NARROW SPECTRUM OF HLA, AND THEIR CHANGES AT THE POPULATION LEVEL OVER TIME IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOPDA103) M. Koga1, A. Kawana-Tachikawa1, T. Odawara1, D. Heckerman2, T. Miura1, A. Iwamoto1 These results indicate that HLA alleles that are protective against HIV-1 infection in a given population, are not necessarily beneficial in the distinct population; and importantly, some alleles are likely losing their protective effects at population level as the epidemic continues. |
| MOPDA104 | THE HLA CLASS II ALLELE DRB1*1303 IS ASSOCIATED WITH REDUCED VIRAL LOADS, INDEPENDENTLY OF HLAB57, IN AN HIV-1 CLADE C INFECTED AFRICAN POPULATION IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOPDA104) B. Julg1,2, E. Moodley2, K. Nair2, M. van der Stok2, K. Bishop2, S. Reddy2, Z. Mncube2, Y. Qi3, P. Goulder1,2,4, B. Walker1,2,5, M. Carrington3, T. Ndung'u2 We demonstrate, for the first time, that the MHC class II allele DRB1*1303 is associated with lower viral load in a Zulu/Xhosa population in South Africa. This is independent of the protection conferred by HLA class I B57. However, this protective activity does not correlate with increased CD4+ T-cell functional responses, suggesting that DRB1*1303 may mediate its protective activity via an alternative mechanism. |
| MOPDA105 | NEW ASSOCIATIONS REPORTED BETWEEN HLA ALLELES AND THE DEVELOPMENT OF MILIARY TUBERCULOUS AND TUBERCULOUS GASTROINTESTINAL DISEASE IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOPDA105) W. Shandera1,2, A. Karstaedt3,4, G. Land5,6 Homozygosity at the DQ allele and/or presence of the DQB1*03XX allele are associated with miliary tuberculous while homozygosity at the HLA-A allele and/or the presence of the HLA-A33 allele are associated with tuberculous gastrointestinal disease. The DQB1*03XX allele may represent a binding site described in the past by serological techniques as DQ1. |
| MOPDB1 – Update on Diagnosing and Monitoring |
|
| MOPDB101 | ACCURATE QUANTIFICATION OF HIV-1 CDNA ON A CREDIT-CARD-SIZED MICROFLUIDIC PLATFORM IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOPDB101) O.T. Ng1, J. Pipper2, S.Y. Wee3, A. Chua4, Y.S. Leo3, J. Husak5, M. Martinkovic5, K.K. Chew3, M. Inoue6 We demonstrate a hand-held device, which accurately quantifies HIV-1 cDNA using duplex real-time PCR. We are currently incorporating direct one-step blood sample preparation to actualize a field-ready device. |
| MOPDB102 | SEMI-QUANTIFICATION OF THE APTIMA HIV-1 SCREENING ASSAY WITH GEN-PROBES' HIGH THROUGHPUT TIGRIS ANALYSER FOR APPLICATION IN SUBTYPE C HIV-1 VIRAL LOAD MONITORING IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOPDB102) L.E. Scott1, L. Berrie2, P. Horsfield3, W.S. Stevens3,4 In this study, the APTIMA HIV-1 Screening assay could be used to determine semi-quantitative VL categories facilitating high throughput screening for ARV treatment switches. This semi-quantitative cut off requires further clinical validation. |
| MOPDB103 | OPTIMIZATION OF ABBOTT M2000 REALTIME HIV-1 VIRAL LOAD ASSAY ON BREASTMILK, DRIED BLOOD SPOTS, SEMINAL PLASMA, AND CEREBROSPINAL FLUID IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOAC303) A. Loftis1, R. Kshatriya1, K. McCall-Culbreath2, S. Fiscus1, J. Nelson1 The Abbott m2000 RealTime HIV-1 assay works well for measuring HIV-1 RNA levels in BMK, semen, CSF, and DBS. More accurate and precise measurements are critical for understanding pathogenesis and transmission, and for clinical trial evaluations. |
| MOPDB104 | HIGH RATES OF FALSE NEGATIVE RESULTS WITH ORAL FLUID AND BLOOD SPECIMENS USING DIFFERENT KITS OF RAPID TESTING FOR HIV DIAGNOSIS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOPDB104) J. Pavie, A. Rachline, B. Loze, L. Niedbalsky, W. Rozenbaum, F. Simon, J.-M. Molina There is variability among kits for rapid diagnosis of HIV infection using blood or oral fluid. This study should help to select the optimal tests for use. |
| MOPDB105 | A NEW PARADIGM FOR INCIDENCE ESTIMATION FROM CROSS-SECTIONAL DATA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPDB105) T.A. McWalter1, A. Welte1,2 This work illuminates some of the issues that have lead to the controversy surrounding incidence measurement from cross-sectional surveys. In particular, it presents a consistent estimator and highlights the crucial role of calibration of that estimator. |
| MOPDC1 – Male Circumcision – Ongoing Research |
|
| MOPDC101 | USING HEALTH FACILITY ASSESSMENT DATA TO STRATEGICALLY ROLL-OUT MALE CIRCUMCISION IN NYANZA PROVINCE, KENYA: A MIXED METHOD APPROACH IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPDC101) A. Herman-Roloff1, E. Llewellyn2, R. Bailey1, K. Agot3 A mixed method approach to analyzing assessment data proved helpful in visually displaying and analyzing the assessment data. At the national level, these results supported the position to lobby for nurses to perform MCs. Locally, NRHS responded to the observed gaps in capacity and geographic coverage of MC services by implementing several service delivery models. |
| MOPDC102 | KNOWLEDGE AND ATTITUDES REGARDING MALE CIRCUMCISION FOR HIV-1 PREVENTION AMONG HETEROSEXUAL HIV-1 SERODISCORDANT COUPLES IN KAMPALA, UGANDA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPDC102) K. Mugwanya1, J. Baeten2, C. Whalen3, C. Celum2, E. Nakku-Joloba4, E. Katabira4 HIV-1 serodiscordant couples in Kampala were highly knowledgeable about the benefits and limitations of MC in reducing men's HIV-1 susceptibility. Nearly 50% of at-risk men were interested in becoming circumcised, a feeling echoed by the majority of their female partners. Our findings are encouraging news for Uganda and other high HIV-1 prevalence countries that are initiating roll-out of MC programs for HIV-1 prevention. |
| MOPDC103 | ACCEPTABILITY OF MALE CIRCUMCISION FOR THE PREVENTION OF HIV/AIDS IN THE DOMINICAN REPUBLIC IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOPDC103) M. Brito1, H. Balbuena2, L. Caso2, R. Bailey3 We believe that rolling out circumcision services in the DR is feasible. An education program aimed at sexually active young males and mothers is essential to increase the acceptance of the procedure in the population. |
| MOPDC104 | SEXUAL SATISFACTION OF WOMEN PARTNERS OF CIRCUMCISED MEN IN A RANDOMIZED TRIAL OF MALE CIRCUMCISION IN RAKAI, UGANDA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOPDC104) G. Kigozi1, I. Lukabwe1, M. Wawer2, D. Serwadda3, F. Nalugoda1, J. Kagayi1, N. Kiwanuka3, F. Mangen Wabwire4, T. Lutalo5, D. Nabukenya1, G. Kigozi Nalwoga1, R. Gray6 The overwhelming majority of women (97.1%) report either no change or improved sexual satisfaction after their male partner was circumcised. These findings suggest that male circumcision has no deleterious effect on female sexual satisfaction. |
| MOPDC105 | LOWER RISK OF HIV INFECTION AMONG CIRCUMCISED MSM: RESULTS FROM THE SOWETO MEN'S STUDY IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: (abstract no. MOPDC105) T. Lane1, H.F. Raymond2, S. Dladla3, J. Rasethe3, H. Struthers3, W. McFarland2, J. McIntyre3 Circumcision may be effective at reducing HIV transmission between men in high prevalence settings such as Soweto where MSM practice a high degree of sexual role segregation. It may be feasible to conduct a randomized controlled trial of circumcision among MSM in such communities. The acceptability and ethical implications of male circumcision in MSM populations must be assessed prior to initiating clinical trials. |
| MOPDC106 | INFORMING DECISION-MAKING ON MALE CIRCUMCISION FOR HIV PREVENTION IN HIGH HIV PREVALENCE SETTINGS: INSIGHTS FROM MODELLING IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPDC106) C. Hankins1, N. Lohse1, T. Hallett2, N. Nagelkerke3, R. White4, L. Abu-Raddad5, H. Weiss4, R. Gray6, J. Stover7, UNAIDS/WHO/SACEMA Expert Group on Modelling the Impact and Cost of Male Circumcision for HIV Prevention Using mathematical modelling to refine and validate a user-friendly tool that can be deployed locally allows decision-makers to indirectly access main modelling findings to estimate HIV incidence, AIDS deaths, overall costs, and net cost per infection averted as a function of procedures performed, service delivery mode, and rate of scale-up. |
| MOPDD1 – Operations Reseach to Improve Laboratory Diagnosis and Monitoring |
|
| MOPDD101 | THE APPLICATION OF EXISTING AND EMERGING TESTING TECHNOLOGIES TO MORE RAPIDLY DETECT HIV INFECTION AMONG HIGH-RISK POPULATIONS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPDD101) K. Roe1, D. Gluth1, S. Gibson1, C. Hall1, T. Ryan1, J. Auerbach2, S. Facente3 Health care and prevention service providers are looking for enhanced rapid testing technologies to screen for AHI. New testing technologies must continue to be explored and advances quickly adapted to reach those at greatest risk in practical and community-relevant ways, in a variety of settings. Lessons learned at Magnet are instructive for the application of enhanced HIV testing and screening techniques in other high incidence and prevalence populations. |
| MOPDD102 | CORRELATION BETWEEN HIV-1 VIRAL LOAD QUANTIFICATION MEASURED IN PLASMA, DRIED BLOOD SPOTS, AND DRIED PLASMA SPOTS USING THE ROCHE Cobas TaqMan ASSAY IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPDD102) M. Andreotti1, M. Pirillo1, G. Guidotti2, S. Ceffa2, G. Paturzo2, P. Germano2, R. Luhanga3, D. Chimwaza4, M.G. Mancini1, S. Vella1, M.C. Marazzi2, L. Palombi5, M. Giuliano1 Reliable results were obtaines with both DBS and DPS when HIV-RNA was >3.5 logs copies/ml. The assay can also be reliably used to identify samples with undetectable HIV-RNA. Our results support the use of DBS/DPS to detect virologic failure in resource-limited settings. |
| MOPDD103 | IDENTIFICATION PATIENT LOSS POINTS FROM TESTING TO TREATMENT INITIATION AMONG INFANTS TESTED IN SWAZILAND IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPDD103) M. Sundaram1, B. Lukhele2 The findings of this study suggest that the greatest points of loss are return of the result to caregivers and enrollment at the ART center for treatment. The study highlighted some of the challenges with the existing sample transportation system, substantial variability among sites, and suggests areas for process improvement. |
| MOPDD104 | AIDS CLINICAL TRIALS GROUP (ACTG) NETWORK LABORATORY QUALITY ASSURANCE (QA) MONITORING: A TOOL TO IMPROVE THE QUALITY OF HIV/AIDS CLINICAL RESEARCH LABORATORIES IN RESOURCE LIMITED SETTINGS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPDD104) A.M. Shahkolahi1, K. Kaiss1, E. Meeks1, R. Coombs2 An integrated EQA laboratory program has been established successfully at 25 international ACTG laboratory sites. This EQA program is essential for evaluating laboratory performance and improving the quality of laboratory data for ACTG clinical trials. |
| MOPDD105 | WHAT IS THE BENEFIT OF CONFIRMING DIAGNOSED IMMUNOLOGICAL FAILURE WITH VIROLOGICAL TESTING IN ART PATIENTS TREATED IN RURAL MALAWI? IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPDD105) M. McGuire1, R. Kanaphathipillai1, R. Mogha1, M. Le Paih2, M. Stover1, B. Méa1, E. Szumilin3, A. Heinzelmann3, E. Mbale4, M. Pujades-Rodríguez5,6 Overall the immunological criteria performed poorly, approximately one third had an undetectable VL and less than a quarter of patients diagnosed with immunological failure had virological failure (as defined by >10,000 HIV RNA copies/mL). Changing treatment on the only basis of immunological criteria would have led to the premature switch of a substantial proportion of patients. |
| MOPDD106 | COST EFFECTIVE MODEL FOR REDUCED SAMPLING OF VIRAL LOADS FOR MONITORING ANTI-RETROVIRAL THERAPY IN RESOURCE LIMITED SETTINGS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPDD106) P. Keiser1,2, S. Ojoo2, I. Mwangi2, N. Smith2 RVLM detected failure later than DHHS testing but significantly sooner than CD4 count monitoring alone, Risk of development of multiple TAMs was low in both VLM schemes but high in CD4 monitoring. Cost of RVLM was higher than CD4 count monitoring alone but less than DHHS monitoring. We conclude that RVLM is a potentially effective method of monitoring ART in resource limited settings. |
| Poster Exhibition Track A - Basic Science Innate immunity responses and function in natural history of HIV infection MOPEA001-MOPEA002 |
|
| MOPEA001 | ELEVATED TYPE I INTERFERON ACTIVITY IS ASSOCIATED WITH HIGH VIRAL LOAD AND LOW CD4 COUNT - ARE INTERFERON RESPONSES GOOD OR BAD IN HIV DISEASE? IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA001) S. Desai1, X. Usuga1, K. Weber2, M. Cohen2,3, A. Landay1 Elevated type I interferon activity in plasma is associated with high viral load and low CD4 counts suggesting that activation of mediators of innate immune pathways may contribute to the pathogenesis of HIV disease. |
| MOPEA002 | INCREASED FUNCTIONAL ACTIVITY OF NK CELLS IN HIV-1-POSITIVE PATIENTS CO-INFECTED WITH GBV-C IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA002) M.T. Maidana Giret1, L. Brian2, H. Tomiyama1, J. Chapman2, B.A.N. Vu2, E.C. Sabino3, D.F. Nixon2, E.G. Kallas1,4 GBV-C leads to decreased in CD161 expressing NK cells and higher frequency of CD107+ NK cells. The elucidation of innate immune mechanisms triggered by GBV-C may give insights into potential immune-mediated protective responses. |
| Poster Exhibition Track A - Basic Science Virus-specific humoral immunity MOPEA003-MOPEA004 |
|
| MOPEA003 | DEVELOPMENT OF INTRA- AND INTER-SUBTYPE CROSS-NEUTRALIZING ANTIBODIES IN HIV-1 SUBTYPE C INFECTION IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA003) M.C. Madiga1, E. Gray1, P. Moore1, K. Mlisana2, S.A. Karim2, C. Williamson3, L. Morris1 Maturation of the neutralizing antibody response from highly type-specific autologous antibodies to those able to cross-neutralize heterologous viruses takes time. After 3 years of infection the frequency of individuals with broad or intermediate breadth was ~20%. In some individuals cross-neutralizing antibodies appeared to target subtype-specific determinants while in others these antibodies may be aimed at a more universal epitope. These latter individuals will be most useful for isolating mAb. |
| MOPEA004 | STIMMUNOLOGY, AN IN-VITRO ANTIBODY PRODUCTION TECHNOLOGY, ENABLES EXPOSURE OF “HIDDEN” INFECTIONS IN CHILDREN - A STUDY OF CHILDREN WITH HIV POSITIVE PARENT(S) AND OF YOUNG ADULTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA004) T. Jehuda-Cohen1,2, J. Mumo3 Detecting all those infected is a key for understanding and curtailing the HIV epidemic. In-vitro stimulation of antibody production has enabled the detection of seronegative HIV infections in both populations. While in the teenager group these findings can be attributed to early detection of recent infection, the findings in the young children is quite puzzling. Some possible mechanism and modes of transmission leading to this phenomenon will be discussed. |
| Poster Exhibition Track A - Basic Science Virus-specific cellular immunity MOPEA005-MOPEA012 |
|
| MOPEA005 | ASSOCIATION OF PROGRAMMED DEATH-1 (PD-1) EXPRESSION ON CD4+CD25nt/hiCD127lo REGULATORY T (Treg) CELLS WITH DISEASE PROGRESSION IN HIV-1 INFECTED PATIENTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA005) Y. Wang, Q.-H. Cao, Y.-L. Xue, P. Zhong, M.-H. Zhuang, L.-Y. Kang, Q.-C. Pan We found that PD-1 expression on peripheral Treg cells was up-regulated and closely correlated with disease progression in HIV-1-infected patients. These findings not only extend our understanding of how Treg cells functions in HIV-1-infected individuals but also support the notion that blocking PD-1/PD-L1 interactions could be a potential therapeutic strategy for HIV-1-infected individuals. |
| MOPEA006 | PRIMARY HIV-1 SPECIFIC CD8+ T CELL RESPONSES INDUCED BY MYELOID DENDRITIC CELLS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA006) C. Rinaldo, B. Colleton, X. Huang, N. Melhem, Z. Fan, L. Borowski, G. Rappocciolo Three major types of myeloid DC targeted by HIV-1 (moDC, LC and idDC) can prime multispecific, polyfunctional CD8+ T cell responses to HIV-1 and other viral antigens. T cell priming by these DC could be an important component of immunogenicity of HIV-1 vaccines. |
| MOPEA007 | ANTIRETROVIRAL THERAPY (ART) CONTROL OF HIV-1 REPLICATION IS ASSOCIATED WITH THE DEVELOPMENT OF DOMINANT HIV-GAG IL-2 CD4 T- CELL RESPONSE IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA007) K. Tsalimalma1, S. Solakidi1, T. Kordossis2, H. Choremi-Papadopoulou1 Dominant Gag-IFN-γ CD4T-cell response is associated with ongoing HIV replication whereas ART mediated viral suppression allows the development of a dominant IL-2 secreting CD4 T cell response, which may represent an important marker of immune reconstitution. |
| MOPEA008 | UPREGULATION OF PD-1 AND CTLA-4 ON HIV-SPECIFIC T CELLS IN HIV-INFECTED INFANTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA008) B. Nqoko, C. Day, N. Mansoor, M. de Kock, J. Hughes, G. Hussey, W. Hanekom The immunoregulatory receptors PD-1 and CTLA-4 are upregulated on HIV-specific CD4+ and CD8+ T cells in HIV infected infants not on ARV. Further studies are necessary to determine the relationship between PD-1 and CTLA-4 expression and HIV-specific T cell dysfunction and disease progression in infants. |
| MOPEA009 | 4-1BB (CD137) EXPRESSION IS DECREASED ON HIV-SPECIFIC IL-2 PRODUCING CD8+ T CELLS IN CHRONIC HIV INFECTION IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA009) A.K. Gizaw1, M. D'Souza1, B.P. O'Connor1, E. Kelly-McKnight1, R. Akkina2, A.P. Fontenot1, B.E. Palmer1 The results of this study indicate decreased expression of 4-1BB on IL-2 producing HIV-specific CD8+ T cells. Thus, decreased expression of 4-1BB may contribute to the loss of HIV-specific CD8+ T cell function and disease progression in subjects with chronic HIV infection. |
| MOPEA010 | IMPORTANCE OF GAG-SPECIFIC CELLULAR IMMUNITY TO CONTROL HIV IN JAPANESE POPULATION IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA010) A. Kawana-Tachikawa1, K. Nakayama1, T. Odawara1, T. Fujii2, A. Iwamoto1,2 Gag-specific CD8+ T cell responses have impact on viral set point in Japanese population. And CD8+ T cell responses against Env and Nef proteins are likely to be consequence of antigen load. |
| MOPEA011 | SPECIFIC ANTI-GAG IMMUNE RESPONSE DURING AND AFTER STRUCTURED TREATMENT INTERRUPTION IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA011) C. Mussini1, E. Nemes2, E. Lugli2, L. Bertoncelli2, M. Nasi2, L. Manzini1, L. Bisi1, M. Pinti2, R. Esposito1, A. Cossarizza2 STI did not result in a preferential depletion of memory cells, or of HIV-specific CD4+ cells, and can induce HIV-specific responses. This strategy does not provoke irreversible immune damages if guided by CD4+ T cell count. |
| MOPEA012 | PROTECTIVE HLA CLASS I ALLELES ARE ASSOCIATED WITH A HIGHER EXPANSION ABILITY OF POLYFUNCTIONAL SUBSETS OF HIV-SPECIFIC CD8+ T CELLS IN LONG TERM NON-PROGRESSORS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA012) M. López1, V. Soriano1, S. Lozano1, J.L. Vicario2, A. Peris1, M. Salgado1, B. Rodés1, N.I. Rallón1, C. Restrepo1, J. González-Lahoz1, J.M. Benito1 The expansion ability of polyfunctional CD8+ T-cell subsets is influenced by the HLA class-I allele and the targeted protein. LTNP with HLA class I protective alleles (specially HLA-B*5701) show a better expansion ability of polyfunctional HIV-specific CD8+ T-cells than the rest, suggesting that other factors might contribute to viral replication control in LTNP without HLA-B*5701 |
| Poster Exhibition Track A - Basic Science Immune responses in resistant cohorts: elite controlers and exposed uninfected MOPEA013-MOPEA015 |
|
| MOPEA013 | LOW HIV-1 VIRAL LOAD ASSOCIATED WITH INCREASED PREVALENCE OF DEFECTIVE PROVIRUSES IN NATURAL VIRAL SUPPRESSORS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA013) L.M. Eyzaguirre1, M.M. Sajadi2, R.R. Redfield2, W.A. Blattner1, J.K. Carr1 Defective proviral genomes were detected in 39.1% of NVS patients, 40.1% of the treated controls and only 23.1% of the untreated controls. The strongest predictor of hypermutation was viral load, which had an inverse relationship with hypermutation. The use of full genome sequencing enabled the entire genome to be characterized and defective viruses of multiple types to be detected. A high rate of defective proviruses was associated with a low viral load and could be either causal or consequential. |
| MOPEA014 | DIFFERENT EVOLUTION OF THE FUNCTIONAL PROFILE OF HIV-SPECIFIC CD8+ T CELLS IN HIV PATIENTS WITH DISTINCT HIV DISEASE PROGRESSION OVER 4 YEARS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA014) A. Peris Pertusa, M. López, N.I. Rallón, C. Restrepo, M. Salgado, B. Rodés, J. González-Lahoz, V. Soriano, J.M. Benito The functional-profile of HIV-specific CD8+ cells may evolve in a different manner depending of the targeted HIV protein and the ability to control virus replication. In patients with uncontrolled HIV replication, the functionality of Gag-specific CD8+ responses tends to diminish over time, whereas in EC it becomes polyfunctional, highlighting its importance in controlling HIV replication. |
| MOPEA015 | CD127 EXPRESSION BUT NOT POLYFUNCTIONALITY OF GAG-SPECIFIC RESPONSE DISCRIMINATES LTNP FROM HIV+ PATIENTS WITH PROGRESSIVE DISEASE IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA015) A. Cossarizza1, E. Nemes1, L. Bertoncelli1, E. Lugli1, M. Pinti1, M. Nasi1, S. Manzini1, L. Manzini2, V. Borghi2, C. Mussini2 Polyfunctionality of Gag-specific T cells is very rare, even in LTNP. Most specific CD4+ cells did not produce TH1 cytokines, but were CD107a+ or CD40L+. Expression of CD127 on CD4+ lymphocytes was the most striking difference between LTNP and PROG or STI patients. |
| Poster Exhibition Track A - Basic Science Mucosal immunity/defenses: responses and dysfunction MOPEA016-MOPEA017 |
|
| MOPEA016 | PERFORIN, GRANZIME-A AND IFN-γ EXPRESSION IN DUODENAL CD8+T CELLS OF HIV-1 CHRONICALLY INFECTED PATIENTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA016) A. Zalar1, M.I. Figueroa2, A. Coraglia3, N. Correa1, P. Bare4, B. Ruibal3, P. Cahn2, M.M. de E de Bracco3, L. Belmonte3 In this study we observed that duodenal CD8+T cells express little Per, GrA and IFN-γ relative to blood, contributing to the inability of CD8+T cells to control HIV. Absence of armed effector cells in duodenal tissue could explain the persistence of viral replication observed in GALT. |
| MOPEA017 | UTERINE EPITHELIAL CELLS REGULATE THE EXPRESSION OF HIV-1 RECEPTORS ON IMMATURE DENDRITIC CELLS VIA TRANSFORMING GROWTH FACTOR BETA (TGF-β)-DEPENDENT MECHANISM IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA017) D. Otieno Ochiel1, P.A. Pioli1, M. Ghosh1, J.V. Fahey1, J.C. Kappes2, C. Ochsenbauer-Jambor3, P.M. Guyer1, C.R. Wira1 Co-culture with recombinant TGF-b1 increased expression of CXCR4 and decreased DC-SIGN expression on DCs. In other studies, CM or recombinant TGF-b1 inhibited the Trans infection of TZM-bl cells with viruses expressing primary HIV-1 env genes. Collectively, our results provide evidence for the regulation of HIV-1 receptors on DCs by UEC and suggest a mechanism for regulation of HIV-1 infection throughout the FRT. |
| Poster Exhibition Track A - Basic Science Novel assays of immune responses MOPEA018-MOPEA019 |
|
| MOPEA018 | T-CELL MARKER ACTIVATION, AND MITOCHONDRIAL MEMBRANE INTEGRITY AFTER EXPOSURE TO LOPINAVIR, RITONAVIR OR EFAVIRENZ ON HIV-NEGATIVE CD4+ LYMPHOCYTES IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA018) J. Scott1, S. O'Barr1, T. Sparrow2 Both LPV and EFV improved CD4 receptor intensity. The combination of LPV/r improved apoptosis markers, which may explain the improved immunologic outcomes seen in ACTG 5142. The results of the T-cell activation markers do not explain the difference in CD4 response seen in that study. Further studies should assess other antiretroviral agents, and the clinical impact of these findings. |
| MOPEA019 | THE EPIGENETIC REGULATION OF SEMAPHORIN 7A (CD108), AN INDUCIBLE COSTIMULATOR OF T CELLS, IS ABNORMAL IN HIV PATIENTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA019) B.P. O'Connor, A. Kassu, M. D'Souza, E. Kelly-McKnight, B.E. Palmer Our results suggest that the T cell defect observed in HIV subjects may in part be due to abnormal epigenetic regulation of costimulatory proteins. |
| Poster Exhibition Track A - Basic Science Correlates of immune protection MOPEA020-MOPEA021 |
|
| MOPEA020 | IMMUNE ACTIVATION PROFILE COMPARISON BETWEEN ELITE CONTROLLERS AND TREATED HIV-1(+) PATIENTS WITH UNDECTABLE PLASMA VIRAL LOAD AND LOW CD4 COUNT RECOVERY IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA020) N. Laufer1,2, M. Carobene1, G. Turk1, O. Sued2,3, Y. Ghiglione1, A. Krolewiecki3, C. Cesar2,3, M. Saracco1, P. Cahn2,3, H. Salomón1 In spite of showing viral suppression similar to EC, TC patients not only don´t recover their CD4 counts but showed an activated phenotype in this cellular population similar to untreated patients indicating that even in the absence of detectable PVL, considerable viral replication must be occurring in reservoirs inducing a stronger immune activation making difficult the regeneration in quantity and quality of their T cells. |
| MOPEA021 | VACCINE-INDUCED IgG2 ANTIBODIES TO HIV ANTIGENS ARE ASSOCIATED WITH PARTIAL SUPPRESSION OF HIV REPLICATION IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA021) M. French1,2, S. Tanaskovic1, A. Lim1, M. Law3, S. Fernandez1, A. Kelleher3, VIR201 Study Group Inclusion of the IFN-γ gene in the vaccine resulted in increased production of IgG2 antibodies to a vaccine encoded antigen, which was associated with partial suppression of HIV replication after ceasing ART. We suggest that induction of IgG2 antibodies to HIV antigens should be investigated as a vaccination strategy. |
| Poster Exhibition Track A - Basic Science Acute and early HIV infection MOPEA022-MOPEA026 |
|
| MOPEA022 | IDENTIFICATION AND PRESENTATION OF PRIMARY HIV-1 INFECTION IN HARARE, ZIMBABWE IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA022) L. Gwanzura1, L. Samaneka1, W. Samaneka1, E. Mudzviti1, M. Mutimuri1, A. Taziwa2, B. Ndemera2, W. Tinago1, G. Mandozana1, J. Hakim3, M. Borok3, T. Campbell4, M. Barron4, E. Connick4 Most clients with PHI were identified from prevention studies. The frequency of PHI was low in GU and PCC where there was a high prevalence of established HIV infection. Targeted screening for STIs or symptoms was neither helpful in PHI identification and presentation. Lymphadenopathy, Fatigue and Myalgia were characteristic for PHI (p- value 0.027, 0.033 and 0.045 respectively). |
| MOPEA023 | IMPACT OF SHORT TERM HAART INITIATED DURING THE ACUTE OR CHRONIC STAGE ON SIV INFECTION OF THE MALE GENITAL TRACT IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA023) A. Le Tortorec1, M. Moreau1, H. Denis1, A.-P. Satie1, O. Bourry2, P. Roques2, B. Jégou1, R. Le Grand2, N. Dejucq-Rainsford1 During the acute stage, HAART dramatically reduces SIV dissemination in the MGT but does not prevent it. During the chronic stage, short term HAART significantly decreases the frequency of SIV DNA detection in all MGT organs, except for the testis. Whether prolonged HAART can eradicate SIV from the MGT will next be investigated. |
| MOPEA024 | GENETIC CHARACTERIZATION AND DETERMINATION OF MULTIPLICITY OF INFECTION USING SINGLE GENOME AMPLIFICATION OF RECENTLY TRANSMITTED HIV-1 ENV VARIANTS FROM A COHORT WITH MULTIPLE CIRCULATING HIV-1 SUBTYPES IN MBEYA, TANZANIA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA024) G.P. Bandawe1, A. Nofemela1, R. Thebus1, J. Marais1, N. Wood2, L. Maboko3, M. Hoelscher4, C. Williamson1 Although a slightly higher proportion of multiple variant transmissions are observed in this cohort there is no evidence to suggest a role for HIV-1 subtype in enhancement or reduction of multi variant transmission. |
| MOPEA025 | MIP-1-ß AND IFN-γ RESPONSES IN ACUTE/EARLY HIV-1 INFECTION IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA025) A. Obuku Ekii1,2, D. Lule Bugembe1, K. Musinguzi1, G. Mutonyi1, J. Levin1, E. Birabwa1, R. Twesigye1, C. Watera1, F. Bawulira1, R. Awuga3, O. Mbabazi3, T. Vudriko1, N. Ndembi1, P. Hughes1, J. Serwanga1, P. Kaleebu4, P. Pala1, Rubicon Cohort MIP-1-ß cultured ELISPOTs paralleled IFN-γ assays, but were positive more often. MIP-1-ß ELISPOTs are here used for the first time to complement the evaluation of T cell responses to HIV-1. |
| MOPEA026 | BIOLOGICAL, GENETIC AND GP160 ENVELOPE CHARACTERIZATION OF B AND NON-B HIV-1 TRANSMITTED VIRUSES: USEFULNESS IN THE VACCINE CANDIDATE ASSESSMENT IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA026) A. Fernandez-Garcia1, T. Cuevas1, M. Muñoz-Nieto1, E. Serrano-Bengoechea2, V. García1, C. Miralles3, M. Pinilla1, M.J. Lezaun4, M. González-Galeano1, A.M. Sanchez1, L. Jimenez-Tormo1, E. Delgado1, M.M. Thomson1, L. Perez-Alvarez1 The availability of a well defined panel including HIV-1 strains of different genetic forms taken during early infection, should be a valuable resource for optimizing and standardizing vaccine candidate assessment. Complete sequencing may be necessary for evaluating clade-specific reactivities. |
| Poster Exhibition Track A - Basic Science Signaling mechanisms and pathways MOPEA027-MOPEA028 |
|
| MOPEA027 | HIV-1-INFECTED CD4+ T LYMPHOCYTES AND MACROPHAGES EXHIBIT DOWN-REGULATION OF CONSTITUTIVE Hsp EXPRESSION AND FAILING HEAT-STRESS RESPONSE IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA027) A. Kabakov, Y. Makarova The HIV-1 infection suppresses the HSF1-mediated stress response in CD4+ T lymphocytes and monocyte-derived macrophages; besides, the constitutive Hsp expression is also down-regulated as a result of the HIV-1 infection. Such a deficiency of Hsps explains the high risk of apoptosis in the infected CD4+ T cells and macrophages as well as their enhanced sensitivity to heat and Hsp90 inhibitors. |
| MOPEA028 | HIV INFECTION MODULATES CELLULAR PROTEINS ASSOCIATED WITH CARDIOVASCULAR DISORDERS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA028) S. Rasheed1, A. Hussain2, J. Yan2, A. Lau2 Chronic HIV-infection augments concomitant expression of novel receptors, enzymes and kinases that are involved in the development of cardiovascular diseases (p=8×10-11). Since HIV replication also enhances production of low density lipoproteins and many key proteins that disrupt lipid metabolism, we conclude that disease-specific pathways have already been triggered by chronic HIV-replication. The risk of developing cardiovascular complications in HIV-infected individuals is then exacerbated by various therapies. Translational studies using the new targets would lead to a better understanding of clinically significant markers that could then be used for early diagnosis of these disorders. This is the first direct evidence that novel biomarkers of coronary heart diseases are modulated directly by HIV-infection. |
| Poster Exhibition Track A - Basic Science Mechanisms of activation/inflammation and impact in pathogenesis MOPEA029-MOPEA034 |
|
| MOPEA029 | IMPACT OF HAART INTERRUPTION ON PLASMA INFLAMMATORY MARKERS ASSOCIATED WITH CARDIOVASCULAR DISEASE. FINAL 36-MONTH RESULTS FROM A RANDOMIZED STUDY IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA029) M.M. Olmo1, C. Alonso-Villaverde2, M. Peñaranda3, F. Gutierrez4, J. Romeu5, M. Larousse6, J. Curto7, P. Domingo8, J.A. Oteo9, P. Sanchez7, D. Podzamczer7, Stopar Study Group HAART interruption lead to an increase in cardiovascular inflammatory markers after 36 months in comparison with continous therapy. As these cytokines correlate with endothelial damage and development of atherosclerotic plaque our data may partially explain the harmful cardiovascular effect of HAART-interruption. |
| MOPEA030 | ATORVASTATIN REDUCES MARKERS OF IMMUNE ACTIVATION WITHOUT AFFECTING BIOMARKERS OF INFLAMMATION IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA030) A. Ganesan1,2,3, N. Crum-Cianflone1,2,4, J. Qin5, C. Rehm6, C. Brandt1,4, J. Vita1,3, S. Mccarthy1,3, A. Rupert7, J. Metcalf8, D. Follmann5, S. Tasker3, F. Maldarelli9 Atorvastatin use resulted in significant declines in atherogenic lipids . Previously reported reductions in immune activation markers were not associated with changes in inflammatory biomarkers; the failure to demonstrate an effect maybe secondary to the small sample size or the shorter duration of follow up. |
| MOPEA031 | DIFFERENTIAL EFFECTS OF ANTI-TUBERCULOSIS TREATMENT ON ACTIVATION OF CD4 AND CD8 T CELL SUBPOPULATIONS FROM HIV/TB CO INFECTED PATIENTS BEFORE ANTIRETROVIRAL TREATMENT IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA031) O.Y. Briceño1,2, E. Espinosa1, G. Reyes-Terán1 The contrast between an overall decrease in CD8 T cell activation and biphasic changes in CD4 T cell activation during TB control suggests that this microorganism contributes to immune activation in HIV disease, but could have suppressive effects on CD4 T cells. Transient CD4 T cell activation could explain changes in viremia and in subpopulation frequencies. |
| MOPEA032 | Abstract Withdrawn |
| MOPEA033 | ACTIVATION LEVELS OF CENTRAL MEMORY CD8 T CELLS DIFFERENTIATE HIV PATIENTS WITH SPONTANEOUS VERSUS HAART-INDUCED CONTROL OF HIV REPLICATION IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA033) M. López, V. Soriano, S. Lozano, A. Peris, M. Salgado, B. Rodés, N.I. Rallón, C. Restrepo, J. González-Lahoz, J.M. Benito Elite controllers show abnormal and higher activation levels of central memory CD8 cells than patients successfully treated with HAART, suggesting that residual viral load may be higher in patients spontaneously controlling viral replication than in those successfully treated with HAART. |
| MOPEA034 | ASSOCIATION BETWEEN ACTIVATION OF INFLAMMATORY AND COAGULATION PATHWAYS AND MORTALITY DURING LONG-TERM FOLLOW UP IN SMART IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA034) N. Paton, The INSIGHT SMART Study Group HIV-infected patients with elevated D-dimer and IL-6 are at increased risk of death, and this association persists, with minimal attenuation, in long-term follow up. The strength and durability of the association suggest that activation of inflammatory and coagulation pathways play an important role in HIV pathogenesis. Further research to establish the aetiology and to evaluate potential therapeutic interventions is warranted. |
| Poster Exhibition Track A - Basic Science Mycobacteria and TB MOPEA035 |
|
| MOPEA035 | LOW COST MOLECULAR BIOLOGY DEDICATED SYSTEM FOR THE RAPID AND SAFE DETECTION OF MYCOBACTERIUM TUBERCULOSIS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA035) E. Garberi1, J. Garberi1, J. Labrador1, J. Peneipil2, L. Scigliano2, A. Troncoso3 Results obtained showed that it could be a very useful tool to increase eficiency detection of tuberculosis disease in low bacilus load samples. Furthermore its relativately low cost and friendly using make it feasible to run in poor development regions. |
| Poster Exhibition Track A - Basic Science Interactions with other pathogens MOPEA036-MOPEA038 |
|
| MOPEA036 | CERVICAL INTRA EPITHELIAL NEOPLASIA AND HIV INFECTION AS APPLIED TO WOMEN SUBJECT TO GYNAECOLOGICAL MEDICAL VISIT IN BUJUMBURA, BURUNDI IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA036) J.O. Niyongere1, T. Niyongabo2, Z. Ndizeye2, S. Henno3, J. Ndikubagenzi4, G. Nsengiyuwva2, J. Nduwimana2, V. Paumier2, P. Noret2 Prevalence of CIN is high. Factors of risk found out include HIV infection, early age sexual intercourse and multi sexual partnership. The neck of the womb cancer being one of the cancers that can heal if detected early, it is crucial to have its systematic detection strengthened especially for VIH+ women. |
| MOPEA037 | METHYLATION REVERSAL IN HIGH GRADE B LYMPHOMA CELL LINES IDENTIFIES NOVEL EPIGENETIC CHANGES CONSERVED BETWEEN IMMUNOCOMPETENT AND HIV POSITIVE HOSTS AND OTHERS SPECIFIC TO HIV-ASSOCIATED LYMPHOMA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA037) T. Crook1, N. Syed2, R. Shah3, A. Papoudou-Bai4, J. Stebbing5, K. Naresh6, M. Tuthill1, M. Nelson7, H. Coley8, E. Hatzimichael9, M. Bower1 We describe a panel of genes subject to transcriptional silencing in high-grade B lymphomas. The similar frequency of methylation observed in immunocompetent and HIV positive patients for a subset of these genes implies that these may be fundamental in suppression of lymphomagenesis. In contrast, other genes are methylated only in HIV-associated cases suggesting important functions in the pathogenesis of lymphomas arising immunocompromised host. Thus, methylation profiling allows rapid molecular discrimination between HIV-associated and sporadic high-grade lymphomas and between atypical DLBCL and BL. |
| MOPEA038 | EXPLOITATION OF HERPESVIRUSES TO SUPPRESS HIV-1 IN COINFECTED TISSUES IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEA038) A. Lisco1, C. Vanpouille1, B. Brichacek1, J. Balzarini2, C. McGuigan3, M. Götte4, R. Schinazi5, L. Margolis1 Interactions between HIV and other viruses, in particular herpesviruses, including the low-pathogenic HHV-6 and HHV-7 can be exploited and mimicked to develop new anti-HIV-1 strategies. |
| Poster Exhibition Track B - Clinical Sciences Interactions with other pathogens MOPEB001-MOPEB005 |
|
| MOPEB001 | INCREASED CLINICAL EVENTS IN HIV-INFECTED PATIENTS WHO ACHIEVE FULL VIROLOGIC SUPPRESSION BUT FAIL TO ATTAIN A CD4 COUNT ≥200 CELLS/MM3 AFTER TWO YEARS OF COMBINATION ANTIRETROVIRAL THERAPY (cART) IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB001) M. Loutfy1,2,3, M. Genebat4, D. Moore5,6, K. Chan5, J. Raboud1,7, A. Shen5, M. Li1,7, M. Klein8,9, R. Hogg5,10, The Canadian Observational Cohort Collaboration (CANOC) In our study population, those taking cART who achieve complete viral suppression but fail to have a CD4 cell increase above the desired target of ≥200c/mm3 have an increased rate of clinical events after two years, confirming the clinical significance of the immunologic discordant state. Our study event rate was low and verification with a larger sample would be beneficial. |
| MOPEB002 | IMPACT OF LEVEL OF EDUCATION IN THE DELAYED DIAGNOSIS OF HIV INFECTION, RESPONSE TO HAART, AND SURVIVAL IN THE COHORT OF THE SPANISH AIDS RESEARCH NETWORK (CoRIS) IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB002) P. Sobrino Vegas1, J. Rodríguez Urrego1, P. Viciana2, J.A. Iribarren3, I. Santos4, I. Gutiérrez5, F. Segura6, M. Riera7, M. Masiá8, J. Sola9, B. Juan5, CoRIS We found that a low level of education was independently associated with delayed HIV diagnosis and a poorer virological response and Immunological response. These finding highlight the need for incorporating equity in policies regarding HIV infection. |
| MOPEB003 | EFFECT OF WHO STAGE 3/4 EVENTS AFTER ART INITIATION ON SURVIVAL OF HIV-INFECTED AFRICAN ADULTS IN THE DART TRIAL IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB003) C. Kityo1, D. Ford2, A.S. Walker2, J. Hakim3, P. Munderi4, F. Lutwama5, F. Ssali1, A. Reid3, H. Grosskurth4, D.M. Gibb2, C.F. Gilks6, A.G. Babiker2 Mortality rates following a WHO stage 3/4 event vary considerably with diagnosis; of note, some WHO 3 events have greater mortality impact than WHO 4 events. More work is needed to evaluate the impact of switching to second-line therapy following an event on mortality risk. |
| MOPEB004 | HIV INFECTED MALE CLIENTS - ? A NEGLECTED LOT IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB004) J.M. Ng´ang´a, N. Kirui Jelagat, F. Muruiki, J. Kimani, J. Kwatampora, G. Kamunyo Male clients seek HIV care at advanced stages. Therefore, there is need to develop targeted interventions for males that enhances early screening, diagnosis and management. |
| MOPEB005 | PRE-ART PLASMA LEVELS OF INFLAMMATION AND COAGULATION MARKERS ARE STRONG PREDICTORS OF DEATH AFTER COMMENCING ART IN A SOUTH AFRICAN COHORT WITH ADVANCED HIV DISEASE IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB005) L. Ledwaba, P. Maja, The Phidisa Predictors of Mortality Substudy Team In a South African cohort with advanced HIV disease, elevated pre-ART CRP, IL-6 and D-dimer are strongly associated with death after commencing ART. Aggressive clinical monitoring may be warranted after commencing ART in patients with elevations in these biomarkers. |
| Poster Exhibition Track B - Clinical Sciences Acute and early infection MOPEB006-MOPEB007 |
|
| MOPEB006 | EVALUATION OF SIX YEARS OF STATEWIDE SCREENING AND TESTING FOR ACUTE HIV INFECTION IN NORTH CAROLINA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB006) J. Kuruc1, A. Mayo2, L. Sampson3, J. Barnhart3, M. Brinson4, E. Foust3, C. Pilcher5, S. McCoy6, C. Gay1, P. Leone1,7, J. Eron1 AHI and chronic HIV prevalence has declined from 2002-2008 but AHI screening still improves diagnostic yield. Adolescents, especially young MSM of color, were more likely diagnosed with AHI. Women were less commonly diagnosed during AHI, potentially due to risk perception but further research is needed. Characterizing populations diagnosed with AHI may provide insight into improving early detection of HIV infection. |
| MOPEB007 | SYMPTOMS AND PHYSICAL EXAMINATION FINDINGS ASSOCIATED WITH HIV SEROCONVERSION IN ZAMBIA, 1994-2008 IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB007) P. Sullivan1, U. Fideli2, E. Chomba3, C. Vwalika3, L. Mwananyanda3, A. Tichacek2, N. Luisi2, S. Allen2 In these African HIV seroconverters, most reported no suggestive symptom. Reported symptoms were non-specific and common in African populations. Adenopathy was the major PE finding. Higher number of symptoms preceeding first positive antibody test was predictive of higher VL set-point. |
| Poster Exhibition Track B - Clinical Sciences New monitoring strategies including rapid tests MOPEB008-MOPEB012 |
|
| MOPEB008 | ANALYSIS OF AN HIV RAPID TESTING ALGORITHM IN COUPLES FROM RWANDA AND ZAMBIA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB008) D. Boeras1, E. Karita2, E. Chomba3, N. Luisi1, A. Tichacek1, E. Hunter1, A. Caliendo1, S. Allen1 Only 5% of clients with indeterminate/discrepant rapid results were HIV-infected. Serial three rapid test algorithms are reliable when two of three are negative. Almost half of those with two of three tests positive proved to be HIV-uninfected. Guidelines should be amended to include repeat testing in such cases. False-positive rapid tests may persist for months but can be distinguished from early infection when repeat testing does not show clear seroconversion. Positive partner serostatus is an important indicator of HIV infection risk and should prompt repeat testing. |
| MOPEB009 | VERY EARLY DIAGNOSIS OF HIV INFECTION IN NEWBORN AT DAY 0-DAY 3 ON DBS IN CAMBODIA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB009) S. Ngin1, L.S. Kruy2, C. Kong3, S. Im2, V. Lim2, M.L. Ek2, D. Augustinova4, K. Koum5, C. Rouzioux6, E. Nerrienet1 These preliminary results demonstrate the feasibility of a minimally invasive very early diagnosis done on DBS, making this approach helpful for screening and improving medical care of HIV exposed children in Cambodia. |
| MOPEB010 | FIELD STUDY OF A DRY BLOOD SPOT NUCLEIC AMPLIFICATION METHOD FOR INFANT HIV DIAGNOSIS AND VIRAL LOAD DETERMINATION IN TANZANIA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB010) S.M. Lofgren1, A.B. Morrissey1, C.C. Chevallier1,2, M. Anangisye3, S. Edmonds4, B. Amos4, D. Sifuna5, J.A. Crump1,2,5,6 DBS provide similar results to plasma for infant diagnosis and viral load testing >1,000 copies/mL. DBS are a promising alternative to liquid plasma for HIV-1 RNA services to remote areas. |
| MOPEB011 | EVALUATION OF CYTO-CHEX® REAGENT ON THE STABILITY OF T CD4+ AND T CD8+ CELL MARKERS IN WHOLE BLOOD SAMPLES IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB011) B.S. Velho1, D. Pellenz1, L.G.A. Borges1, A.C. Vanni1, S.K. Kato1, L.R. Motta1, R.D. Sperhacke1, C.D. Pilcher2, R.S. Souza1 The Cyto-Chex® reagent appears to maintain integrity of white blood cell antigens for CD4 and CD8 enumeration for up to 11 days, providing additional time for sample shipment and processing to a flow cytometry laboratory. This could be an important tool in resource-poor settings where refrigeration and other ancillary laboratory equipment may not be available at collection sites. |
| MOPEB012 | RAPID HIV TESTING IN A LARGE URBAN EMERGENCY DEPARTMENT IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB012) E. Lowman1, J. Harper2, S. Jain3, M. Livak1, A. Kessler1, Y. Shem-Tov2, D.P. Rumoro2, H.A. Kessler1, K. Smith1 No false positive rapid HIV results using oral mucosa swabs were detected. Our seroprevalence rate suggests we should adopt routine universal testing in the ED. The acceptance rate of rapid HIV testing in our patient population and the percentage of patients receiving results was higher than other recent reports. Reasons for the better performance in our study requires further investigation. |
| Poster Exhibition Track B - Clinical Sciences Sexually transmitted infections (STI) MOPEB013-MOPEB018 |
|
| MOPEB013 | HIV AND SYPHILIS IN ZAMBIA: RESPONSE TO PENICILLIN THERAPY IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB011) J. Dionne-Odom1, M. Conkling2, B. Vwalika2, J. Mulenga2, E. Chomba2, C. del Rio1, S. Allen3 Syphilis continues to be a significant problem in Zambia, particularly among patients with HIV. In early syphilis, a more rapid response to benzathine penicillin among female patients is documented. Consistent with prior reports, HIV status does not appear to delay response to first line therapy with penicillin. |
| MOPEB014 | ANALYSIS OF ANTIBIOTIC SENSITIVITY FOR “HIGH LEVEL” RESISTANT URETHRITIS AND CHRONIC PROSTATITIS CAUSED BY UREAPLASMA UREALYTICUM STRAINS IN HIV SEROPOSITIVE MALE PATIENTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB014) M. Vasylyev1, M. Sluzhynska1, O. Sluzhynska2, Y. Netak2 According obtained data best choice for treatment is doxycyline azithromycin and clindamycin. In all patients combination and concentration of susceptible drugs toward the agent were different. In that case cultural diagnostic (DUO) and detection of individual antibiotic sensitivity (SIR) toward U.U. strains in HIV infected patients is very important for rational and successful treatment. |
| MOPEB015 | SEXUALLY TRANSMITTED INFECTION INCIDENCE RELATIVE TO TIME SINCE CARE ENTRY IN A LONGITUDINAL HIV CLINICAL COHORT IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB015) A.J. Mayo1, S. Napravnik2, B. Stalzer2, E.B. Quinlivan2, J.J. Eron2 Regular care for HIV is also beneficial towards reducing STI incidence; however, rates did not decline until patients were in care for more than two years. Targeting HIV-prevention efforts and STI screening to patients during the early years after care entry might be especially important. |
| MOPEB016 | NATIONAL SERO-PREVALENCE OF HERPES SIMPLEX VIRUS TYPE 2 AND CO-INFECTION WITH HIV-1: RESULTS OF THE 2007 KENYA AIDS INDICATOR SURVEY IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB016) N. Mugo1,2, S. Dadabhai3, K. Sabin4,5, I. Baya6, J. Muttunga7, W. Omwomo8, R. Bunnell9, I. Mohammed10, R. Kaiser9 Over 6 million adults were HSV-2-infected at the time of KAIS. Prevalence varied by sex, marital status and male circumcision. HSV-2 infected individuals were 8 times more likely to be infected with HIV-1. Those HSV-2-infected but HIV-uninfected are at increased risk for HIV-1 acquisition, especially in HIV-discordant relationships. |
| MOPEB017 | SYPHILIS TREATMENT RESPONSES IN A COHORT OF HIV-INFECTED PATIENTS WITH OEN ACCESS TO CARE ARE SIMILAR TO THOSE REPORTED IN HIV-UNINFECTED PATIENTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB017) A. Ganesan1,2,3, A. Fieberg1,4, A. Weintrob1,2,5, M. Landrum1,2,6, V. Marconi1,2,6, A. Spaulding4, C. Bradley1, V. Barthel1,7, N. Crum-Cianflone1,2,8, A. Lifson1,4, B. Agan1,2 Contrary to prior reports seroreversion was common and syphilis treatment failure rare among HIV-infected patients in our cohort, suggesting open-access to care maybe associated with better treatment response. |
| MOPEB018 | LOW SEROPREVALENCE OF SYPHILIS IN BURKINA FASO IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB018) F. Kirakoya1, N. Nagot2 The low prevalence of syphilis among pregnant women and the adult general population is very encouraging and should not challenge the amount of resources dedicated to STI and HIV prevention in the country. |
| Poster Exhibition Track B - Clinical Sciences Prophylaxis of HIV associated infections; vaccines e.g. pneumococcal, hepatitis and HPV, co-trimoxazole prophylaxis and IPT MOPEB019-MOPEB024 |
|
| MOPEB019 | HIGH PREVALENCE OF DRUG RESISTANCE AMONGST HIV-EXPOSED AND INFECTED CHILDREN WITH CULTURE CONFIRMED TUBERCULOSIS ENROLLED ON A TUBERCULOSIS PREVENTION TRIAL IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB019) A. Hesseling1, S. Kim2, S. Madhi3, S. Nachman4, S. Schaaf5, T. Victor6, C. Mitchell7, A. Violari8, G. McSherry9, M. Cotton10 The high prevalence of DR TB amongst HIV-exposed and infected children is consistent with reports of increasing DR in South Africa. Failure of IPT due to exposure to INH-resistant organisms may have contributed to P1041 findings. DST should be routine in all children with tuberculosis in HIV-endemic settings. Contact investigation should include bacteriologic data in index cases. |
MOPEB020 | IMPACT OF DAILY COTRIMOXAZOLE PROPHYLAXIS IN SEVERELY IMMUNOSUPPRESSED ADULTS IN AFRICA STARTED ON COMBINATION ART IN THE DART TRIAL IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB020) C.F. Gilks1, D. Ford2, A.S. Walker2, P. Munderi3, J. Hakim4, C. Kityo5, F. Lutwama6, H. Grosskurth3, A. Reid4, F. Ssali5, P. Mugyenyi5, D.M. Gibb2, A.G. Babiker2 Cotrimoxazole prophylaxis should be provided with cART in resource-limited settings for at least 72 weeks. |
| MOPEB021 | GOOD TUBERCULOSIS TREATMENT OUTCOMES AND NO EVIDENCE OF INCREASED DRUG RESISTANCE IN INDIVIDUALS PREVIOUSLY EXPOSED TO ISONIAZID PREVENTIVE THERAPY IN A POPULATION WITH HIGH HIV PREVALENCE IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB021) C.L. van Halsema1, V. Chihota2, K. Fielding3, E. Russell3, J. Lewis3, F. Mota2, G. Pilane2, P. Molefe2, G. Churchyard2, A. Grant1 TB disease in individuals recently exposed to IPT has characteristics and outcomes similar to background. Prevalence of isoniazid resistance was not significantly different from control. Increase in prevalence (but not incidence) of isoniazid resistant cases is expected if IPT effectively reduces incidence of isoniazid-sensitive TB. Most cases were in HIV-positive individuals and may be due to recent infection since starting IPT. |
| MOPEB022 | A SEQUENTIAL VACCINATION STRATEGY WITH CONJUGATED AND POLYSACCHARIDE PNEUMOCOCCAL VACCINES COMPARED WITH THE POLYSACCHARIDE VACCINE ALONE IN HIV PATIENTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB022) M. Penaranda1, A. Payeras2, A. Cambra3, M. Riera1, J. Mila3 Pneumococcal vaccine response was poor in both strategies without differences between them. Sequential vaccination with both vaccines does not add any improvement in terms of specific antibodies increase to the recommended vaccination. |
| MOPEB023 | DELAYING ANTIRETROVIRAL THERAPY (ART) RESULTS IN FUNCTIONALLY IMPAIRED ANTIBODY PRODUCTION TO PNEUMOCOCCUS CONJUGATED VACCINE (PCV) IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB023) S.A. Madhi1,2, M. Cotton3, A. Violari4, P. Jean-Philippe5, J. Mcintyre4, S. Meadows6, S. Nachman7, H. Käyhty8, K.P. Klugman2, P. Adrian1,2, on behalf of the CIPRA-ZA-4 Team Although ART deferral does not affect the quantity of antibody however delaying initiation of ART results in functionally-impaired antibody production to PCV, supporting recommendation for early initiation of ART in infants. |
| MOPEB024 | EFFECT OF HIV EXPOSURE AND ANTIRETROVIRAL THERAPY ON QUANTITATIVE ANTIBODY CONCENTRATION TO PNEUMOCOCCAL CONJUGATE VACCINE (PCV) IN INFANTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB024) S.A. Madhi1,2, P. Adrian1,2, M. Cotton3, J. Mcintyre4, P. Jean-Philippe5, S. Meadows6, S. Nachman7, K. P.Klugman2, H. Käyhty8, A. Violari4, on behalf of the CIPRA-ZA-4 Team HIV+ children, irrespective of when ART is initiated have similar antibody concentration to PCV compared to HIV- children, however antibody functionality may differ. |
| Poster Exhibition Track B - Clinical Sciences Neurologic and psychiatric manifestations MOPEB025-MOPEB028 |
|
| MOPEB025 | HIV-ASSOCIATED SENSORY NEUROPATHY: A COMPARISON OF RATES AND RISK FACTORS IN AUSTRALIA AND SOUTH AFRICA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB025) A. Wadley1, C. Cherry2,3,4, P. Price5, J. George6, J. Affandi5, K. Smith7, P. Kamerman1 The prevalence of sensory neuropathy was similar in these two ethnically and gender diverse populations of HIV-positive patients. However, neuropathy risk factors differed between the two groups, except for the common association between increasing age and neuropathy risk. |
| MOPEB026 | TRENDS OVER TIME AND RISK FACTORS FOR SUICIDE IN HIV-INFECTED INDIVIDUALS AND THE GENERAL SWISS POPULATION, 1988-2008 IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB026) O. Keiser1, A. Spoerri1, M. Brinkhof1, B. Hasse2, A. Gayet-Ageron3, F. Tissot4, H. Furrer5, M. Battegay6, P. Schmid7, E. Bernasconi8, M. Egger1, and the Swiss HIV Cohort Study Suicide rates decreased substantially with the introduction of HAART, however, they remain above the rate observed in the general population. |
| MOPEB027 | HIGH RATES OF ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT (ANCI) IN HIV-1 INFECTED SUBJECTS RECEIVING STABLE COMBINATION ANTI-RETROVIRAL THERAPY (CART) WITH UNDETECTABLE PLASMA HIV RNA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB027) L. Garvey1,2, D. Yerrakalva1, A. Winston1,2 We have observed high rates of aNCI in a UK cohort of patients stable on CART, particularly in younger individuals. Possible explanations for these findings include an increased susceptibility of younger adults to the effects of HIV on the brain or differing education and socioeconomic status between our cohort and control data. |
| MOPEB028 | PREVALENCE OF HIV-1-ASSOCIATED NEUROCOGNITIVE DISORDERS IN ARGENTINA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB028) K. Goodkin1,2, P. Cahn3, M. Concha4, L. Abusamra3, E. Lopez1,2, J. Kogan3 The prevalence rate of HAND, overall, was 52.4%, a high rate. The prevalence of HAD was much higher than that currently reported for HIV infected persons in the USA; in contrast, the prevalence of MCMD in Argentina was only slightly higher than that reported in the USA. These results could be related to the use of a solely clinic-based sample in Argentina rather than mixed clinic and community-based samples accrued in the USA. Other explanations include differences in antiretroviral adherence, neurovirulence of viral sub-types circulating in Argentina and the USA, and in CNS-penetration of antiretroviral regimens used. Further research on the differential prevalence of HAND across cultures of primary Spanish speakers internationally is warranted. |
| Poster Exhibition Track B - Clinical Sciences Clinical trials - phase I/II MOPEB029-MOPEB031 |
|
| MOPEB029 | PHARMACOKINETIC-PHARMACODYNAMIC-VIRAL DYNAMICS MODELING OF MONOTHERAPY DATA FOR THE NNRTI, LERSIVIRINE (UK-453,061), IN HIV-1-INFECTED SUBJECTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB029) B. Poland1, L. McFadyen2, P.L.S. Chan2, B. Weatherley2 The PK IIV and residual variability for lersivirine tablet were low. The pharmacodynamic and viral dynamics parameters showed much higher IIV. Simulations were used to explore doses as well as other risk factors on long term clinical outcome. |
| MOPEB030 | SUSTAINED ANTIRETROVIRAL EFFICACY OF RALTEGRAVIR AS PART OF COMBINATION ART IN TREATMENT-NAÏVE HIV-1 INFECTED PATIENTS: 144-WEEK DATA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB030) E. Gotuzzo1, B.-Y. Nguyen2, M. Markowitz3, F. Mendo4, W. Ratanasuwan5, C. Kovacs6, G. Prada7, J. Morales-Ramirez8, C. Crumpacker9, C. Lu2, D. Brown2, R. Isaacs2, K. Strohmaier2, R. Danovich2, H. Teppler2, and the Protocol 004 Part II Study Team In ART-naïve pts, RAL with TDF/3TC had potent and durable antiretroviral activity, which was similar to EFV/TDF/3TC and was sustained to week 144. RAL was generally well tolerated; drug related AEs were less frequent in pts treated with RAL compared to EFV. |
| MOPEB031 | ONCE-A-DAY PAEDIATRIC HAART WITH DDI+3TC+EFV IN WEST AFRICA: 24 MONTH VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES. ANRS12103/12167 TRIAL IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB031) H. Hien1, B. Nacro2, E. Zouré2, H. Tamboura3, A. Ouiminga4, F. Rouet4, A. Drabo4, S. Yaméogo5, A. Hien5, H. Peyrière6, J. Nicolas7, P. Van De Perre7, P. Msellati8, S. Diagbouga1 Once-a-day 3TC + DDI + EFV HAART in HIV children is well tolerated and is associated with virological success and immune reconstitution. |
| Poster Exhibition Track B - Clinical Sciences Clinical trials - phase III/post-licensing MOPEB032-MOPEB044 |
|
| MOPEB032 | PRELIMINARY SAFETY RESULTS OF CO-ADMINISTRATION OF NEVIRAPINE (NVP) OR EFAVIRENZ (EFV), AND RIFAMPICIN (RMP) IN HIV-TUBERCULOSIS (TB) CO-INFECTED PATIENTS IN MAPUTO (MOZAMBIQUE): CARINEMO-ANRS 12146 TRIAL IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB032) N.B. Bhatt1, E. Baudin2, I.V. Jani1, L. Ciaffi3, M. Luggli3, R. Bastos4, P. Samo Gudo5, D. Arakaki6, C. Michon7, A. Calmy8,9, M. Bonnet10, and the ANRS 12146 Study Group The absence of severe rash, the relatively low number of severe hepatitis and definitive treatment interruptions due to hepatitis are reassuring but need to be further confirmed. |
| MOPEB033 | DIFFERENCES IN VIROLOGIC RESPONSE AMONG AFRICAN-AMERICANS AND FEMALES REGARDLESS OF THERAPY IN THE HEAT STUDY IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB033) K.Y. Smith1, P.N. Kumar2, P. Patel3, N.C. Bellos4, L. Sloan5, P. Lackey6, D.H. Sutherland-Phillips3, C. Vavro3, L. Yau3, M.S. Shaefer3 Differences in CD4+ and virologic responses by sex and race at week 96 were observed. Notably, fewer African-Americans and females achieved VL< 50 c/mL in both arms and in both analyses suggesting these differences may be multifactorial. Slightly greater CD4+ increases were observed in females and although African-Americans had lower initial CD4 counts, immunologic recovery was similar across other racial groups and between groups over 96 weeks. Further investigation into the underlying differences in response is required. |
| MOPEB034 | EFFECTS OF ONCE-DAILY DARUNAVIR/RITONAVIR VERSUS LOPINAVIR/RITONAVIR ON LIPID PARAMETERS AND ANTHROPOMETRICS IN TREATMENT-NAÏVE HIV-1-INFECTED ARTEMIS PATIENTS AT WEEK 96 IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB034) E. Baraldi1, J. Morales-Ramírez2, S. Schneider3, A. Stoehr4, A. Orani5, C. Vanden Abeele6, L. Lavreys6 Once-daily DRV/r 800/100mg was less frequently associated with elevations in triglycerides and total cholesterol than LPV/r 800/200mg total daily dose. DRV/r patients had significantly greater increases in weight and BMI versus LPV/r. The favourable lipid profile seen with DRV/r at Week 48 was also demonstrated at Week 96. |
| MOPEB035 | COMPARABLE SAFETY AND EFFICACY WITH ONCE-DAILY (QD) VERSUS TWICE-DAILY (BID) DOSING OF LOPINAVIR/RITONAVIR (LPV/R) TABLETS WITH EMTRICITABINE (FTC) + TENOFOVIR DF (TDF) IN ANTIRETROVIRAL (ARV)-NAÏVE, HIV-1-INFECTED SUBJECTS: 96 WEEK RESULTS OF THE RANDOMIZED TRIAL M05-730 IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB035) J. Gonzalez-Garcia1, D. Cohen2, M. Johnson3, L. Sloan4, L. Fredrick2, J. Rublein2, C. Naylor2, B. da Silva2, B. Bernstein2, on behalf of the M05-730 Study Team QD LPV/r shows a durable response in ARV-naïve, HIV-1-infected subjects and has similar efficacy to BID, regardless of baseline disease characteristics. LPV/r tablets dosed QD and BID are equally well tolerated and have a similar high barrier to resistance. |
| MOPEB036 | ETRAVIRINE (ETR; TMC125) DEMONSTRATES DURABLE EFFICACY IN TREATMENT-EXPERIENCED PATIENTS IN THE DUET TRIALS: POOLED 96-WEEK RESULTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB036) A. Mills1, P. Cahn2, J.-M. Molina3, S. Nijs4, J. Vingerhoets4, J. Witek5 The results from the pooled DUET 96-week analysis demonstrate the superior durable efficacy of ETR over placebo. Patients in the ETR group maintained undetectable VL through 96 weeks, with only a 3% drop from Week 48 (57% vs 60%). In addition, higher responses were observed with ETR versus placebo, irrespective of number of active agents, baseline ETR FC or weighted score. |
| MOPEB037 | EFFICACY, SAFETY AND PHARMACOKINETIC PROFIL OF A SIMPLE ANTIRETROVIRAL REGIMEN CONTAINING UNBOOSTED ATAZANAVIR, DIDANOSINE EC AND LAMIVUDINE IN NAÏVE HIV-1 INFECTED PATIENTS IN SENEGAL (REYADAK STUDY-IMEA-031) IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB037) R. Landman1, M.-B. Diallo2, G. Peytavin1, C. Touré Kane3, S. Mboup3, M.B. Koita Fall2, B. Ndiaye2, Y. Bennai4, P.M. Girard5, P.S. Sow2 Good safety and immuno-virological efficacy of this triple drug therapy were demonstrated in this population . First line unboosted ATV containing regimen could be an alternative to WHO NNRTI preferred regimens and deserves further evaluation in a comparative study in Africa. |
| MOPEB038 | LONG-TERM SAFETY PROFILE OF ETRAVIRINE IN TREATMENT-EXPERIENCED, HIV-1-INFECTED PATIENTS: POOLED 96-WEEK RESULTS FROM THE PHASE III DUET TRIALS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB038) T. Campbell1, B. Grinsztejn2, J. Hartikainen3, S. Nijs4, J. Witek5 ETR was well tolerated in treatment-experienced HIV-1-infected adults over 96 weeks and continues to demonstrate a tolerability profile similar to placebo. Rash, which was mostly mild-to-moderate and occurred early, was the only AE associated with ETR treatment. |
| MOPEB039 | CONCURRENT USE OF STATINS DOES NOT INFLUENCE EFFICACY OF MARAVIROC IN MOTIVATE STUDIES IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB039) G. Moyle1, N. Rajicic2, H. Valdez2, H. Mayer2, J. Goodrich3 The antiviral efficacy of MVC in patients with R5 HIV does not appear to be influenced by co-administration with statins. |
| MOPEB040 | VIROLOGIC SUPPRESSION ON MARAVIROC IN TREATMENT-NAÏVE PATIENTS WITH R5 HIV-1 IS SIMILAR TO EFAVIRENZ AT HIGH BASELINE VIRAL LOAD, AND MARAVIROC DISCONTINUATIONS FOR ADVERSE EVENTS ARE LESS LIKELY TO SHOW DRUG RESISTANCE: 48-WEEK RESULTS FROM THE MERI IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB040) M. Nelson1, A. Lazzarin2, G. Di Perri3, R. Campo4, R. Wood5, J. Goodrich6, J. Heera6, E. van der Ryst7, H. Mayer6, M. Tawadrous6, C. Craig7, M. Westby7 Relative to MERIT, the MERIT-ES reanalysis showed improved MVC responses at week 48 across randomization strata, particularly for those with high baseline viral load. EFV DAEs were less likely to be suppressed before drug withdrawal and more likely to be associated with the development of drug resistance. |
| MOPEB041 | EFFICACY AND SAFETY OF ATAZANAVIR/R VS. LOPINAVIR/R IN TREATMENT-NAÏVE PATIENTS WITH ADVANCED DISEASE: CASTLE STUDY 96-WEEK RESULTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB041) J. Uy1, R. Yang2, V. Wirtz2, L. Sheppard3, J. Absalon2 Higher response rates at lower baseline HIV RNA were seen for ATV/r vs. LPV/r. High response rates across all CD4 cell count strata were observed for ATV/r. ATV/r and LPV/r had consistent AE profiles within each arm by baseline HIV RNA. More grade 2-4 treatment-related AEs were observed with LPV/r at low baseline CD4 cell counts. |
| MOPEB042 | GRACE (GENDER, RACE AND CLINICAL EXPERIENCE): 48-WEEK RESULTS OF DARUNAVIR/R-BASED THERAPY IN THE LARGEST TRIAL IN NORTH AMERICA FOCUSED ON TREATMENT-EXPERIENCED WOMEN IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB042) K. Squires1, J. Currier2, D. Bridge3, D. Hagins4, C. Zorrilla5, R. Ryan6, R. Falcon7, A. Tennenberg7, J. Mrus7, on behalf of the GRACE Study Group Experience with GRACE demonstrates that it is possible to enroll large numbers of women and people of color from North America in antiretroviral treatment trials. The higher rate of discontinuation among women, which was driven by reasons other than virologic failure, highlights the need for additional focus on retaining diverse populations in future trials. Through 48 weeks of therapy, there were no statistical differences in virologic response rates between women and men receiving darunavir/ritonavir, and no clinically relevant sex-based differences in AEs. AEs were generally comparable to those seen in previous studies of darunavir/ritonavir in treatment-experienced patients. Additional subgroup analyses, including race/ethnicity, are ongoing. |
| MOPEB043 | CLINICAL ENDPOINTS REDUCED THROUGH ETRAVIRINE USE IN TREATMENT-EXPERIENCED, HIV-1-INFECTED PATIENTS: POOLED 96-WEEK RESULTS FROM THE PHASE III DUET TRIALS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB043) J. Eron1, R. Haubrich2, P. Reiss3, M. Thompson4, R. Weber5, S. Nijs6, J. Witek7 In addition to improving virological endpoints, ETR demonstrated reductions in ADI/D versus placebo through 96 weeks of treatment. In both treatment groups, few patients had new adjudicated ADIs between Weeks 48 and 96. |
| MOPEB044 | SIMILAR DECLINES IN HIV-1 RNA (VIRAL LOAD, VL) FROM BASELINE (BL) TO 96 WEEKS OBSERVED IN SUBJECTS RANDOMIZED TO ABC/3TC OR TDF/FTC EACH WITH LOPINAVIR/RITONAVIR IN THE HEAT TRIAL (EPZ104057) IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB044) L. Yau, J. Hernandez, P. Patel, L. Dix, K. Pappa, M. Shaefer These analyses did not reveal any differences in the HIV-1 RNA profiles between the treatment arms over 96 weeks. The comparable viral dynamics and long-term profiles suggest similar intrinsic potency of the two triple regimens studied. |
| Poster Exhibition Track B - Clinical Sciences When to start therapy MOPEB045-MOPEB050 |
|
| MOPEB045 | RETENTION AND ATTRITION OF PATIENTS COMMENCED ON HAART AT LADYSMITH PROVINCIAL HOSPITAL IN SOUTH AFRICA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB045) M.S.H. Khan The main cause of attrition was death with the majority of the death occurring within the first 12 month due to patients being commenced on ARV when the CD4 count is <200.Death as a cause of attrition can be reduced if patients are commenced on ARV when CD4 count is <350. |
| MOPEB046 | MORTALITY RATE AMONG MALNOURISHED HIV-INFECTED CHILDREN IN KAMPALA, UGANDA: IMPLICATIONS FOR TIME TO INITIATE HAART IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB046) A. Kekitiinwa1, A. Maganda1, P. Tumbu1, A. Asiimwe Rwego1, E. Kiboneka2 Early initiation of HAART was associated with an almost three-fold increased risk of death. The optimal time to start HAART and mortality aetioogy in malnourished children initiating HAART early needs further evaluation, possibly through a randomized controlled trial. Meanwhile, HAART should be withheld until malnourished children have stabilized. |
| MOPEB047 | PROGRESS REPORT ON THE TEMPRANO ANRS 12136 TRIAL: EARLY ANTIRETROVIRAL TREATMENT AND 6-MONTH CHEMOPROPHYLAXIS WITH INH IN ABIDJAN, CÔTE D'IVOIRE IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB047) D.R. Moh1, C. Danel1, E. Ouattara1, D. Gabillard2, H. Menan3, F. Bohoussou1, J. Lecarrou2, A. Badjé1, S. Eholié1, X. Anglaret1 So far, we observed a good acceptance of being recruited into a trial of early ART initiation, and an easiness of ruling out active TB before INH prophylaxis in patients with high CD4 counts. |
| MOPEB048 | IMMUNOLOGIC RESPONSE AND SURVIVAL OF INFANTS INITIATING ANTIRETROVIRAL TREATMENT (ART) AT LESS THAN ONE YEAR OF AGE COMPARED TO OLDER CHILDREN ENROLLED AT MTCT-PLUS INITIATIVE SITES IN 8 AFRICAN COUNTRIES AND THAILAND IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB048) R.J. Carter, M. Katyal, P. Toro, E.J. Abrams, for the MTCT Plus Initiative Infants initiating ART had higher mortality at the beginning of treatment. However, surviving infants showed good immunological response over >3 years of follow-up, indistinguishable from older children. |
| MOPEB049 | THE IMPACT OF ANTIRETROVIRAL THERAPY ON THE BASIC REPRODUCTIVE NUMBER, R0 IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB049) M. Lurie1, B. Williams2, P. Kumar3 Initiating ART at 200 CD4 cells/µL has little public health benefit in terms of reducing incident infections. In order to achieve a maximum preventive effect, ART would have to be initiated significantly earlier in the natural course of HIV/AIDS. |
| MOPEB050 | TIME TO REACHING CD4≤500 FOR INDIVIDUALS FOLLOWED-UP SINCE HIV SEROCONVERSION IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB050) S. Lodi1, K. Porter1, A. Phillips2 50% of individuals would require treatment within 20 months of seroconversion, should guidelines indicate initiation of therapy at CD4≤500. These data may be useful for planning healthcare resources. |
| Poster Exhibition Track B - Clinical Sciences First line therapy MOPEB051-MOPEB060 |
|
| MOPEB051 | VIROLOGIC AND IMMUNOLOGIC RESPONSES TO EFAVIRENZ OR BOOSTED LOPINAVIR AS FIRST THERAPY FOR PATIENTS WITH HIV IN THE SWISS HIV COHORT STUDY (SHCS) IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB051) H.C. Bucher1,2, J. Young1, H. Günthard3, M. Rickenbach4, C.A. Fux5, B. Hirschel6, M. Cavassini7, P. Vernazza8, E. Bernasconi9, M. Battegay2, and the Swiss HIV Cohort Study Patients on EFV compared to LPV/r have a lower risk of virologic failure and this risk seems independent of their CD4 count when starting therapy. Patients on EFV also appear more likely to maintain an expected rate of CD4 cell increase unless they start therapy with an advanced infection. |
| MOPEB052 | FOUR-YEAR TREATMENT OUTCOMES FOR ANTIRETROVIRAL THERAPY IN A COHORT OF ADULT PATIENTS IN KAMPALA, UGANDA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB052) M.R. Kamya1, A. Kasirye-Kiragga2, B. Castelnuovo2, A. Kambugu2, F.C. Semitala1, I. LwangaS2, C. Katabira2, R. Colebunders3, D.L. Thomas4, Y. Manabe2,4 Our data indicate a high post-ART mortality but surviving patients experienced sustained viral suppression and low treatment failure rates on first-line regimens. Patients who received NVP (compared to EFV) and those with poor adherence were more likely to fail treatment. |
| MOPEB053 | THE TOKEN STUDY: SAFETY & EFFICACY OF TRUVADA OR KIVEXA IN COMBINATION WITH EFAVIRENZ IN TREATMENT NAÏVE PREDOMINANTLY BLACK AFRICAN HIV PATIENTS, A PROSPECTIVE COHORT STUDY IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB053) S. Das1, J. Arumainayagam2, I. Ahmed-Jushuf3, E. Carlin3, B. Kumari1, S. Chandramani2, L. Riddle4, M. Pammi3, S. Acharya2, M. Ghanem5, TOKEN Study Group Truvada and Kivexa in combination with efavirenz in treatment naïve HLA-B 5701 negative predominantly black African patients are safe and effective. |
| MOPEB054 | DARUNAVIR/RITONAVIR ONCE DAILY: A SINGLE CENTRE COHORT EXPERIENCE IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB054) C. Scott, J. Dunning, A. Teague, M. Bower, B. Gazzard, M. Nelson In this cohort of treatment naïve and experienced patients with no background PI resistance, once daily darunavir/ritonavir (900/100mg) is both effective in terms of virological suppression and well tolerated. |
| MOPEB055 | KIVEXA VERSUS TRUVADA: SIMILAR VIROLOGICAL OUTCOMES IN ART-NAÏVE PATIENTS STARTING A LOPINAVIR/RITONAVIR-BASED REGIMEN - 48-WEEK-DATA FROM THE STAR AND STELLA COHORTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB055) C. Koegl1, A. Baumgarten2, B. Bieniek3, S. Holm4, M. Hower5, H. Jaeger6, T. Lutz7, M. Mueller8, W. Schmidt9, A. Trein10, R. Pauli11, E. Wolf1, R. Petry12, H.-J. Stellbrink13 This prospective non-interventional study did not show a difference in virological response between subjects using KVX or TVD in conjunction with LPV/r adjusted for baseline VL and CD4-count. |
| MOPEB056 | TWO YEAR VIROLOGICAL OUTCOMES IN HIV-1 INFECTED ZAMBIAN CHILDREN USING ADULT TRIOMUNE (FIXED DOSE COMBINATION d4T, 3TC AND NVP) IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB056) R.K. Gupta1, D. Ford2, D. Kabamba3, V. Mulenga3, M. Kalumbi4, C. Kalengo3, R. Chileshe3, P. Grant5, S. Kirk5, M. Thomason2, A. Ferrier2, A.S. Walker2, C. Chintu3, D. Pillay6,7, D.M. Gibb2 Virological failure >1000c/ml at 24 months in 103 children surviving 6 months on HAART was between 26% and 50% (assuming all without known/inferred values were not or were failures respectively). Resistance to NNRTI/lamivudine was high in virological failures, and emerging NRTI resistance would compromise recommended 2nd line NRTIs in 5/26 children. |
| MOPEB057 | LONG-TERM RANDOMISED COMPARISON OF CLINICAL OUTCOMES FOLLOWING ART INITIATION WITH TRIPLE-NUCLEOSIDE (COMBIVIR/ABACAVIR) OR NNRTI-BASED (COMBIVIR/NEVIRAPINE) THERAPY IN AFRICA: THE NORA SUBSTUDY OF THE DART TRIAL IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB057) A.S. Walker1, P. Munderi2, C. Kityo3, A.G. Babiker4, F. Ssali3, A. Reid5, H. Grosskurth2, P. Mugyenyi3, D.M. Gibb4, C.F. Gilks6, DART Trial Team There was no statistically significant difference in the rate of new WHO 4 events/death between participants initiating ART with Combivir plus nevirapine versus abacavir through 5 years follow-up. |
| MOPEB058 | COMBINATION THERAPY WITH TENOFOVIR DF (TDF)/ EMTRICITABINE (FTC) AND EFAVIRENZ LEADS TO SUSTAINED AND FAVOURABLE RESPONSES IN A LARGE OUTPATIENT COHORT (GERMAN TRUVADA COHORT) IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB058) A. Zoufaly1, S. Hertling1, G. Faetkenheuer2, T. Lutz3, S. Klauke3, A. Stoehr4, S. Mauss5, K. Schewe6, B. Ranneberg7, J. van Lunzen1 In this cohort, PI-based and NNRTI-based regimens in combination with Truvada led to high virological success rates comparable to those in randomized controlled trials. However, EFV-based regimens are more durable in daily clinical practice. |
| MOPEB059 | TAMS PREVENTION IN FIRST-LINE HAART IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB059) F. Maggiolo1, M. Airoldi2, D. Ripamonti1, T. Bini3, G. Gregis1, G. Quinzan1, C. Martinelli4, D. Valenti1, F. Suter1 The studied regimens show an high virologic efficacy and are well tolerated. In the case of virologic failure the PI-based HAART seems to present an higher genetic barrier to viral mutations and the AZT/TDF backbone does not prevent the selection of TAMs despite a described in-vitro mutual protective effect. K65R mutation appears only when the DDI/3TC backbone is associated to EFV. |
| MOPEB060 | RESPONSE TO FIRST LINE ANTIRETROVIRAL THERAPY AMONG HIV-INFECTED PATIENTS WITH AND WITHOUT A HISTORY OF INJECTING DRUG USE IN INDONESIA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB060) R. Wisaksana1,2, A. Indrati1,2, E. Rogayah1,2, A. Fibriani2, B. Alisjahbana1,2, P. Sudjana1,2, T. Djajakusumah1,2, A. van der Ven2,3, R. van Crevel2,3 These data are the first systematic evaluation of first line ART in Indonesia. Many HIV-patients in this setting have a history of IDU, which is associated with more advanced HIV-AIDS, but not with reduced uptake, retention or success of ART. |
| Poster Exhibition Track B - Clinical Sciences Management of late presenters MOPEB061 |
|
| MOPEB061 | LATE PRESENTATION IS FREQUENT IN THE ELDERLY, IN FEMALE AND IN PATIENTS FROM HIGH PREVALENCE COUNTRIES IN A GERMAN OUTPATIENT COHORT IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB061) J. van Lunzen1, G. Fätkenheuer2, T. Lutz3, S. Klauke4, S. Mauss5, C.K. Schewe6, B. Bieniek7, C. Mayr8, A. Stoehr9, H. Jessen10, H. Knechten11, L. Gallo12, B. Ranneberg12 Late presentation was common in this German outpatient cohort. After 48 weeks, virological outcome in LP and non-LP was comparable, while new Aids-defining events were reported more frequently in LP. Late presenters are older, more often women and from high prevalence countries. Prevention and testing strategies should try to take this into account. |
| Poster Exhibition Track B - Clinical Sciences Simplification strategies (induction/maintenance and use of bPI monotherapy MOPEB062-MOPEB064 |
|
| MOPEB062 | SIMPLIFYING ANTIRETROVIRAL TREATMENT IN VIRALLY SUPPRESSED CHILDREN BY SWITCHING FROM DOUBLE BOOSTED PROTEASE INHIBITORS TO LOPINAVIR/RITONAVIR MONOTHERAPY IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB062) T. Bunupuradah1, P. Lumbiganon2, T. Puthanakit1, J. Ananworanich1,3, T. Mengthaisong1, P. Boonrak1, P. Phanuphak1, D. Burger4, C. Pancharoen5, P. Kosalaraksa2, HIV-NAT 077 85% of children had VL <50 copies/ml at 6 months of simplification from dPI to mLPV/r. mLPV/r was effective and safe in the children who adhered to it. However, long term monitoring is warranted. |
| MOPEB063 | THE FOTO STUDY: THE 48 WEEK EXTENSION TO ASSESS DURABILITY OF THE STRATEGY OF TAKING EFAVIRENZ, TENOFOVIR AND EMTRICITABINE FIVE DAYS ON, TWO DAYS OFF (FOTO) EACH WEEK IN VIROLOGICALLY SUPPRESSED PATIENTS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB063) C. Cohen1, A. Colson1, G. Pierone2, E. Dejesus3, F. Kinder4, R. Elion5, D. Skiest6, A. Habel1, J. Jensen1, J. Garb7, H. Schrager1, D. Back8 The FOTO strategy maintains virologic suppression through 48 weeks. There was a strong preference to take 2-days off treatment per week even when on a simple one-pill once-daily regimen. The 28% cost savings for this strategy has broad potential implications for the developed and developing world. |
| MOPEB064 | LIPOPOLYSACCHARIDE (LPS) CHANGES IN PLASMA OF HIV-1-INFECTED SUBJECTS DURING REPEATED TREATMENT INTERRUPTIONS IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB064) L. Palmisano, S. Baroncelli, C.M. Galluzzo, M.F. Pirillo, M.G. Mancini, L.E. Weimer, V. Fragola, M. Giuliano, S. Vella Our results confirm a strong association between HIV-1 RNA and LPS levels. The increase in this marker after one year of intermittent HAART suggests that repeated episodes of uncontrolled viral replication, even if of limited duration, may partially reverse the favourable effects of HAART on immune activation. |
| Poster Exhibition Track B - Clinical Sciences Switch studies MOPEB065-MOPEB070 |
|
| MOPEB065 | HIGH RATE OF MISCLASSIFICATION OF TREATMENT FAILURE BASED ON WHO IMMUNOLOGICAL CRITERIA IN RESOURCE LIMITED SETTINGS IN UGANDA IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB065) A. Kiragga, P. Schaefer, A. Kambugu, B. Castelnuovo Almost three-quarters of patients fulfilling the WHO criteria for immunological failure had an undetectable VL; in RLS affordable viral load testing should be made available to prevent unnecessary switches to second line therapy. |
| MOPEB066 | SWITCH FROM ENFUVIRTIDE TO RALTEGRAVIR IN VIROLOGICALLY SUPPRESSED MULTIDRUG-RESISTANT HIV-1 INFECTED PATIENTS: FINAL RESULTS OF THE RANDOMIZED ANRS 138 TRIAL (EASIER) IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th:(abstract no. MOPEB066) N. De Castro1, J. Braun2, I. Charreau2, P. De Truchis3, F. Jeanblanc4, R. Verdon5, L. Slama6, J.-L. Meynard7, J.-P. Aboulker2, J.-M. Molina1,8, ANRS 138 Easier In patients with multidrug-resistant HIV-infection receiving a suppressive antiretroviral regimen, a switch to raltegravir was safe, well tolerated and virologically non inferior to the maintenance of enfuvirtide. |
| Poster Exhibition Track B - Clinical Sciences Therapy for the heavily pre-treated patient MOPEB071-MOPEB075 |
|
| Poster Exhibition Track B - Clinical Sciences Clinical trials and antiretroviral therapy MOPEB076-MOPEB091 |
|
| Poster Exhibition Track B - Clinical Sciences Therapeutic vaccine and immune-based therapy trials MOPEB092 |
|
| Poster Exhibition Track C - Biomedical Prevention Interactions with other pathogens MOPEC001-MOPEC013 |
|
| Poster Exhibition Track C - Biomedical Prevention Behavioural research in the context of biomedical prevention MOPEC014-MOPEC042 |
|
| Poster Exhibition Track D - Social, behavioural and economic science Accuracy, feasibility, cost, and utility of laboratory tests MOPED001-MOPED007 |
|
| Poster Exhibition Track D - Social, behavioural and economic science Methods to ensure uninterrupted stocks of commodities and drugs MOPED008-MOPED010 |
|
| Poster Exhibition Track D - Social, behavioural and economic science Cost-benefit and cost effectiveness studies MOPED011-MOPED018 |
|
| Poster Exhibition Track D - Social, behavioural and economic science Economic strengthening initiatives (e.g., micro-finance, health insurance MOPED019-MOPED020 |
|
| Poster Exhibition Track D - Social, behavioural and economic science Sustainability of financing MOPED021-MOPED025 |
|
| Poster Exhibition Track D - Social, behavioural and economic science Cross national comparison MOPED026-MOPED028 |
|
| Poster Exhibition Track D - Social, behavioural and economic science Efficiency and equity in access to treatment and prevention MOPED029-MOPED038 |
|
| Poster Exhibition Track D - Social, behavioural and economic science National and regional program effectiveness and coverage MOPED039-MOPED052 |
|
| Poster Exhibition Track D - Social, behavioural and economic science Impact of donor agencies and on national responses MOPED053-MOPED056 |
|
| Poster Exhibition Track D - Social, behavioural and economic science Vertical and horizontal health system collaborations MOPED057 |
|
| Poster Exhibition Track D - Social, behavioural and economic science Collaboration between HIV, TB and malaria programmes MOPED058-MOPED059 |
|
| Poster Exhibition Track D - Social, behavioural and economic science Impact of HIV interventions on the health sector MOPED060-MOPED064 |
|
| Poster Exhibition Track D - Social, behavioural and economic science Case studies of successful operational research programmes MOPED065-MOPED068 |
|
| Poster Exhibition Track D - Social, behavioural and economic science Linking operational research to changes in practice and policy MOPED069-MOPED081 |
|
| Tuesday – Oral Sessions TUAA1 – Induction and Maintenance of Viral Latency |
2007-07-22
Main Table of Contents
Copyright © 2009 - International AIDS Society (IAS). All information and content relating to the abstracts from the 5th International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.